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ABSTRACT
Introduction: Antiepileptic-antidepressant combinations are frequently used by clinicians; their
pharmacokinetic (PK) and pharmacodynamic (PD) drug interactions (DIs) have not been wellstudied but are frequently likely to be clinically relevant.
Areas covered: This article provides a comprehensive review of PK DIs between antiepileptics and
antidepressants. In the absence of PD DI studies, PD information on pharmacological mechanisms
and studies on efficacy and safety of individual drugs are reviewed.
Expert opinion: The clinical relevance of the inductive properties of carbamazepine, phenytoin,
phenobarbital and primidone, and the inhibitory properties of valproic acid and some
antidepressants are well understood; correction factors are provided if appropriate DI studies have
been completed. More PK studies are needed for: i) antiepileptics with potent inductive effects for
all recently approved antidepressants; ii) high doses of mild CYP3A4 inducers, such as clobazam,
eslicarbazepine, oxcarbazepine, rufinamide and topiramate for reboxetine and vilazodone; iii)
valproate as a possible inhibitor, mild inducer, or both a mild inducer and competitive inhibitor of
some antidepressants; and

iv) inhibitory effects of long-term fluoxetine use on clobazam,

lacosamide, phenobarbital, primidone, carbamazepine, felbamate, tiagabine, and zonisamide.
Possible synergistic or additive beneficial PD DIs in generalized anxiety disorder, chronic pain,
migraine prophylaxis, weight control, and menopausal symptoms need study.
Keywords:

antiepileptics;

antidepressants;

drug

interactions;

pharmacodynamics;

pharmacokinetics.

Highlights box
-Pharmacokinetic (PK) and pharmacodynamic (PD) drug interactions (DIs) in antiepileptic and
antidepressant combinations have not been well-studied but are frequently likely to be clinically
relevant.
-More PK studies are needed for establishing dose-correction factors for i) antiepileptics with
potent inductive effects for all recently approved antidepressants; ii) high doses of clobazam,
eslicarbazepine, oxcarbazepine, rufinamide and topiramate, for reboxetine and vilazodone; iii)
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fluvoxamine as an inhibitor of clobazam, lacosamide, phenobarbital, and primidone; iv) fluoxetine
as an inhibitor after several months of co-prescription for clobazam, lacosamide, phenobarbital,
primidone, carbamazepine, felbamate, tiagabine, and zonisamide; v) high doses of sertraline as an
inhibitor of valproate and lamotrigine; and vi) tricyclic antidepressants as inhibitors of lacosamide
and clobazam.
-PD DI studies on antiepileptic-antidepressant combinations, information on the pharmacological
mechanism and the efficacy and safety studies of individual drugs is provided to raise awareness of
the potential for PD DIs.
-Possibly synergistic or additive beneficial PD DIs are: i) adding pregabalin to an antidepressant for
generalized anxiety disorder; ii) combining carbamazepine, gabapentin, oxcarbazepine, or
pregabalin with serotonin and noradrenaline reuptake inhibitors (SNRIs), or tricyclic
antidepressants (TCAs) for chronic pain; iii) combining topiramate or valproic acid with
amitriptyline or venlafaxine for migraine prophylaxis; iv) combining bupropion and zonisamide or
topiramate for weight control; and v) combining gabapentin with SNRIs or selective serotonin
reuptake inhibitors (SSRIs) for menopausal symptoms.
-Possibly synergistic or additive harmful PD DIs are some combinations of antiepileptics and
antidepressants increasing the risk for sedation, weight gain, hyperlipidemia, nausea, urinary
retention, hyponatremia, torsades de pointes,
osteoporosis.

hepatic failure, hemorrhages,

heat stroke and
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1. Introduction
Antiepileptic drugs are traditionally divided into first- and second-generation compounds. In
addition to the treatment of epilepsy, antiepileptics are extensively prescribed for the management
of several non-epileptic neurological and psychiatric conditions [1, 2]. In general, compared to the
older drugs, newer antiepileptics have more advantageous pharmacokinetic characteristics, a wider
therapeutic index, a more favorable tolerability and safety profile, and lower potential for drug
interactions (DIs). For these reasons, despite the lack of definitive studies directly comparing the
efficacy of first-generation and second-generation agents [3, 4], newer antiepileptics, particularly
lamotrigine, levetiracetam and oxcarbazepine, have partially replaced older compounds in
developed countries. Among first-generation agents, valproate is the only drug still prescribed as a
first-line drug in males and non-fertile females. It is not a first choice in females of fertile age due to
its teratogenicity potential.
Currently available antidepressants include older or classic agents, such as tricyclic
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), and newer antidepressants,
such as selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake
inhibitors (SNRIs) and other antidepressants with varying mechanisms of action 5. Over the past
two decades, the newer antidepressants, particularly SSRIs, have become the drugs of choice for the
management of depressive disorders, mainly because of their improved tolerability and safety
profile as compared to TCAs. Antidepressant drugs are also widely used for the treatment of other
psychiatric conditions including anxiety disorders, obsessive-compulsive disorder (OCD), eating
disorders, and various forms of chronic pain such as diabetic neuropathic pain and fibromyalgia 5.
Antiepileptics and antidepressants are often prescribed together in patients with several
heterogeneous conditions. Combined use is more likely for more recent compounds, which often
exhibit a wider spectrum of indications. The incidence of depressive disorders in epileptic patients
is estimated to be 30%–70% in their lifetime [6, 7]. Therefore, due to this strict relationship
between epilepsy and mood disorders, antidepressants are frequently co-prescribed in patients with
epilepsy [8-11]. Valproate, carbamazepine and lamotrigine, when used as mood stabilizers, are
frequently associated with antidepressants for the treatment of bipolar disorder [12-15]. Evidence
for efficacy in bipolar disorder also exists for oxcarbazepine [16]. International guidelines for the
treatment of neuropathic pain also include combined treatment with antidepressants and
antiepileptics [17]. Pregabalin and gabapentin are commonly prescribed with a TCA or SNRI for
this condition [18, 19]. Pregabalin is approved for the treatment of generalized anxiety disorder in
Europe and articles frequently recommend adding it to antidepressants for the treatment of
generalized anxiety disorder with comorbid mood depression [20, 21]. Moreover, antidepressants
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may be co-prescribed with topiramate and valproate for migraine prophylaxis, or exclusively to
treat migraine comorbid with depression [22, 23].
Considering the frequent co-prescription of antiepileptics and antidepressants, it is essential
for clinicians to be aware of the potential DIs between these compounds. The consequences of a DI
can be either beneficial, if the interaction results in increased therapeutic efficacy or reduced risk of
adverse drug reactions (ADRs), or harmful, if it leads to decreased efficacy or enhanced toxicity of
one or more of the administered medications. Based on their mechanisms, DIs can be classified into
two main categories, pharmacokinetic (PK) and pharmacodynamic (PD).
In recent years, a number of comprehensive reviews of clinically relevant pharmacokinetic
DIs involving antiepileptics 24-28 or antidepressants 29-33 or combinations [34, 35] have been
published. The aim of the present article is to provide an updated review of clinically significant
DIs between antiepileptics and antidepressants including not only PK DIs but also PD DIs.
Articles for this review were obtained from a PubMed search with no time limit. Searches
were performed for each of the antiepileptics and antidepressants. Only articles published in peerreviewed journals were included, while meeting abstracts were excluded. Information was also
obtained from the individual product inserts of each antiepileptic or antidepressant. Additional DI
information was also obtained from citations of the articles that were retrieved during our search,
and these were also included in our review. This search was beyond the articles previously found
and listed in the authors’ published literature reviews and DI studies.

2. Basic mechanisms of DIs between antiepileptics and antidepressants
2.1 PK DIs
PK DIs consist of changes in the absorption, distribution, metabolism or excretion of a drug
and/or its metabolite(s) after the addition of another drug. These DIs are associated with a
modification in plasma concentration of either the drug or its metabolite(s) and usually are easily
verified by therapeutic drug monitoring (TDM). PK parameters of antiepileptics and antidepressants
are summarized in Tables 1 and 2, respectively.
To our knowledge, no clinically relevant DI has been described so far during at the
absorption phase or protein binding [36-37] between compounds of these two drug classes.
The vast majority of clinically important PK DIs between antiepileptics and antidepressants
occur at a metabolic level and usually involve the hepatic cytochrome P450 (CYP) system and, to a
lesser extent, the uridine diphosphate glucuronosyltransferase (UGT) system 38. Knowledge of
the properties of the major drug-metabolizing enzymes with identification of substrates, inhibitors,
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and inducers of different CYP isoforms can provide some clues to clinicians as to the likelihood of
a clinically relevant DI occurring [38]. In principle, concomitant treatment with drugs metabolized
by the same enzyme or coadministration of a drug with another medication acting as an inhibitor or
inducer involves a DI risk. A number of drug-related (i.e., potency and concentration/dose of the
inhibitor/inducer, therapeutic index of the substrate, extent of metabolism of the substrate through
the affected enzyme, presence of active metabolites), patient-related (i.e., age, genetic
predisposition) and environmental factors (i.e., smoking)

will then influence the potential

occurrence, magnitude, and clinical significance of a metabolic DI [37]. As shown in Tables 1 and
2, most antiepileptics (with the exception of gabapentin, pregabalin and vigabatrin) and
antidepressants are extensively metabolized via CYPs or UGTs. As many compounds of these two
therapeutic classes share common metabolic pathways, potential DIs may be anticipated.
Furthermore, antiepileptics may be involved in metabolically-based DIs because they act as
inhibitors or inducers of various drug-metabolizing systems. Among first-generation agents,
carbamazepine, phenytoin, phenobarbital and primidone (enzyme-inducing antiepileptics) induce
the activity of CYP1A2, CYP2C9, CYP2C19 and CYP3A4, as well as UGTs and epoxide
hydrolase. Valproic acid is a broad-spectrum inhibitor of various drug-metabolizing enzymes
including CYP2C9 and UGTs and, recently, some inductive effects have been demonstrated. The
newer antiepileptics are associated with limited enzyme-inducing potential compared with oldergeneration compounds. However, clobazam, eslicarbazepine, felbamate, oxcarbazepine (at dosages
≥ 1200 mg/day), rufinamide and topiramate (at dosages ≥ 400 mg/day) can induce the activity of
CYP3A4 and, possibly, some UGTs (Table 1). Some of the newer antiepileptics may at times act as
enzyme inhibitors. Eslicarbazepine, felbamate, oxcarbazepine and topiramate are weak inhibitors of
CYP2C19, while stiripentol is a potent inhibitor of CYP1A2, CYP2C19, CYP2D6 and CYP3A4.
Concerning older antidepressants, in vitro evidence indicates that TCAs may inhibit the activity of
CYP2C19 (moderately) and CYP2D6 (weakly) [39]. On the other hand, some newer antidepressant
agents including fluoxetine, fluvoxamine, paroxetine, duloxetine and bupropion, act as potent or
moderate inhibitors of various CYPs and may therefore impair the elimination of antiepileptic
agents metabolized via these isoforms 29, 31, 32.
PK DIs between antiepileptics and antidepressants may theoretically occur during the
excretion phase. While some newer antiepileptics such as gabapentin, pregabalin, vigabatrin,
levetiracetam and topiramate are eliminated predominantly through the kidneys, antidepressants are
predominantly eliminated by drug metabolism. Only desvenlafaxine and milnacipran are largely
excreted unchanged in the urine. So far, there are no reports of clinically significant DIs between
antiepileptics and antidepressants at the renal excretion level.
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PK DIs between antiepileptics and antidepressants may also involve drug transporters, in
particular, P-glycoprotein (P-gp), which plays an important role in the absorption, distribution and
excretion of a wide variety of therapeutic agents 40. As some antiepileptics and antidepressants
may be substrates, inducers or inhibitors of P-gp 41-43, it can be speculated that some DIs
between antiepileptics and antidepressants previously believed to be CYP-mediated are now also
considered to be due to the modulation of multidrug-transporters.
2.1.1 PKs of inducer antiepileptics and endogenous substrates
Some ADRs from potent inducers may be explained by the induction of endogenous
compounds [44-53], but they may manifest only after the organism has not been able to compensate
for these disturbances in homeostasis present for months or years (Figure 1),
2.2 PD DIs
The importance of PD mechanisms of antiepileptics and antidepressants are often underestimated in most articles reviewing DIs. This subsection briefly lists the PD properties of
antiepileptics and antidepressants; they are described more comprehensively in Figures 2 to 5 and
their detailed footnotes. At the end of this section, a subsection comments on the types of PD DIs.
2.2.1 PDs of antiepileptics
Figure 2 summarizes the mechanism of action of antiepileptics in epilepsy, bipolar disorder,
anxiety, pain, migraine prophylaxis, weight loss and other indications. Figure 3 summarizes the
mechanism of action of antiepileptics associated with major safety issues.
2.2.2 PDs of antidepressants
Figure 4 summarizes antidepressant mechanisms of action in several disorders including
depression, OCD, anxiety, pain, weight loss and other indications. Textbooks usually report that
the majority of antidepressants act by inhibiting reuptake transporters but the chronology of
reuptake inhibition does not match the chronology of antidepressant response 5, 54. Only four
TCAs, amitriptyline, clomipramine, imipramine, and nortriptyline, are described in the figures and
tables. Figure 4 lists SSRIs, SNRIs and other newer antidepressants with different mechanisms.
Nefazodone and MAOIs are not included in this article. Figure 5 summarizes antidepressant
mechanisms of action associated with major safety issues.
2.2.3. Pharmacological knowledge and PD DIs
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PD DIs result in a modification of the pharmacological action of a drug by a direct effect on
its site of action or, alternatively, by interfering with another physiological mechanism related to
drug action. Therefore, they occur without any change in the plasma concentration and are more
difficult to recognize and quantify than PK DIs. PD DIs can be classified as additive (i.e., equal to
the sum of the effects of the individual drugs), synergistic (i.e., the combined effects are greater
than expected from the sum of individual effects) or antagonistic (i.e., the combined effects are less
than additive) [37]. They can involve beneficial effects (increased efficacy and/or safety) or harmful
effects (decreased efficacy and/or safety).

3. Specific DIs between antiepileptics and antidepressants
3.1 PK DIs
3.1.1 Effect of antiepileptics on the PKs of antidepressants
First-generation antiepileptics
The first-generation antiepileptics, namely carbamazepine, phenytoin, phenobarbital and
primidone, may induce antidepressant metabolism, as they are powerful inducers of several drugmetabolizing enzymes including CYPs, specifically CYP1A2, CYP2A6, CYP2B6, CYP2C9,
CYP2C19, CYP3A4, as well as UGTs such as UGT1A1, UGT2B7, and UGT2B15.
Early PK studies [34] have repeatedly documented that, concomitant treatment with
enzyme-inducing antiepileptics was associated with a decrease in plasma concentrations of various
TCAs. Because the demethylation of TCAs is catalyzed by multiple isozymes, including CYP2C19
and, to a lesser extent, CYP1A2, CYP2C9 and CYP3A4 [55, 56], induction of these isoforms is the
most likely explanation for the observed PK changes. Another major enzyme contributing to the
metabolism of TCAs, in particular to the hydroxylation reactions, CYP2D6 is generally regarded to
be non-inducible, even though in two formal kinetic studies the 2-hydroxylation of desipramine, a
reaction primarily catalyzed by CYP2D6, was found to be accelerated by carbamazepine and
phenobarbital [57, 58]. In a subsequent investigation in 13 patients with major depression stabilized
with imipramine, the addition of carbamazepine, at a dose of 400 mg/day for two weeks, caused a
significant decrease in mean steady-state concentrations of imipramine and its active metabolite
desipramine, by 42% and 41%, respectively, while the free concentrations of both imipramine and
desipramine increased [59]. The authors speculated that carbamazepine may affect not only the
metabolism of imipramine and desipramine, but also their protein binding. Irrespective of the
mechanism of the interaction, the decrease in plasma concentrations of TCAs is likely to have
clinical implications and individual patients on long-term treatment with enzyme-inducing
antiepileptics may require higher doses to achieve an optimal therapeutic response.
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Regarding SSRIs, phenobarbital, phenytoin and carbamazepine have been reported to
decrease by about 25% the plasma levels of paroxetine, probably as a result of accelerated
metabolism [60, 61]. Administration of carbamazepine, an inducer of CYP3A4, was associated with
a marked decrease in plasma sertraline concentrations in two patients, resulting in lack of
antidepressant efficacy [62]. In an open pilot study involving 6 patients with major depression
stabilized on citalopram (40-60 mg/day), a 4-week augmentation therapy with relatively low doses
of carbamazepine (200-400 mg/day) caused a significant decrease in plasma concentrations of Scitalopram and R-citalopram by 27 and 31% (both, p < 0.05), respectively [63]. This effect was
attributed to nonstereoselective induction of CYP3A4-mediated N-demethylation of citalopram by
carbamazepine.
Carbamazepine, a CYP3A4 inducer, 200 mg twice a day for 32 days, caused a 20% decrease
in milnacipran plasma concentrations [64]. Two PK investigations evaluated the reciprocal
interaction between the new antidepressant mirtazapine (30 mg/ day) and carbamazepine (400
mg/day) or phenytoin (200 mg/day) in healthy subjects under steady-state conditions [65, 66]. In
the first study, coadministration with carbamazepine in 24 healthy volunteers caused a mean
reduction by 39% in the peak plasma concentration (Cmax) of mirtazapine and by 61% in the area
under the plasma concentration-time curve (AUC) [65]. Similarly, addition of phenytoin to 17
healthy male subjects resulted in a mean decrease of the Cmax of mirtazapine by 33% and in its
AUC by a 47% decrease [66]. The reduction in mirtazapine concentrations is presumably due to
induction of CYP3A4-mediated metabolism of mirtazapine by carbamazepine and phenytoin.
Carbamazepine may also induce the biotransformation of bupropion, a new antidepressant which
inhibits the reuptake of noradrenaline and dopamine. In a study involving 12 patients with mood
disorders given a single 150 mg dose of bupropion, addition of carbamazepine, at a mean dose of
942 mg/day, was found to decrease the Cmax of bupropion by 87% (p<0.001) and its AUC by 90%
(p<0.001) [67]. Carbamazepine increased the AUC of its metabolite hydroxybupropion by 50%
(p<0.05). As hydroxybupropion may contribute to therapeutic or adverse effects, the clinical
significance of this DI has not yet been established. A case report described two patients with low
serum concentrations of reboxetine in relation to the dose during carbamazepine or phenobarbital
treatment probably mediated by CYP3A4 induction [68].
Valproate has traditionally been considered a broad-spectrum metabolic enzyme inhibitor. It
inhibits CYP2C9 competitively, CYP2C19 and CYP3A4 weakly and has no effects on CYP1A2,
CYP2D6, and CYP2E1. It inhibits UGT enzymes (UGT1A4 and UGT2B7) [37]. However, a
human hepatocyte study surprisingly demonstrated that valproate may induce some enzymes
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(CYP3A4 and P-gp gene expression) [69]. Moreover, recent clinical studies indicate that valproate
may behave as a mild inducer in some circumstances [70].
Two studies have reported a 50% to 60% elevation in plasma amitriptyline and nortriptyline
concentrations in depressed patients comedicated with valproate [71, 72]. In a PK investigation in
15 healthy subjects, the mean AUC and Cmax for the sum of amitriptyline and nortriptyline
increased by 42% and 19%, respectively, after the addition of valproate [73]. Moreover, an
elevation of serum nortriptyline or clomipramine concentrations in association with valproate
comedication was observed in case reports [74-75]. Severe ADRs associated with a considerable
increase in serum levels of TCAs during valproate treatment has been described in case reports [7678]. Unterecker et al. [79] have recently evaluated the influence of valproic acid on amitriptyline
and nortriptyline serum concentrations by a retrospective analysis of TDM data under naturalistic
conditions. When comparing 33 patients receiving amitriptyline in combination with valproic acid
versus 33 patients on amitriptyline monotherapy, dose-corrected serum concentrations of
amitriptyline, nortriptyline and their sum were significantly higher (p<0.001), by 67%, 128% and
94%, respectively, in patients on comedication. The interaction between valproate and TCAs may
be explained by an inhibitory effect of valproate on CYP2C9 and, possibly, CYP2C19 and
CYP3A4, which play a role in the biotransformation of TCAs [55, 56]. In a subsequent study based
on the same TDM database, the same authors [80] examined the potential DI between valproic acid
and doxepin and venlafaxine, an SNRI agent. The mean dose-corrected serum concentrations of
doxepin plus N-doxepin in 16 patients who received valproic acid comedications were significantly
higher (by 124%, p<0.01) than in the matched controls of patients on doxepin alone. The mean
dose-corrected serum concentrations of venlafaxine plus O-desmethylvenlafaxine in 41 patients
receiving valproic acid comedications did not differ significantly from those of the matched
controls. However, the dose-corrected serum concentrations of the active metabolite Odesmethylvenlafaxine were significantly higher (by 27%, p<0.02) in patients treated with the
combination of valproic acid with venlafaxine. The increase in serum concentrations of doxepin
plus N-doxepin is attributed to the inhibitory effect of valproate on CYP2C9 [81]. To explain the
elevation of serum concentrations of O-desmethylvenlafaxine, the authors speculate that the
inhibition of the CYP2C9-mediated N-demethylation of venlafaxine by valproate may lead to a
stronger O-demethylation and, as a consequence, to higher serum levels of O-desmethylvenlafaxine
[82]. Unlike carbamazepine, valproic acid did not affect the metabolism of bupropion in patients
with depression [67].

Second-generation antiepileptics
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Compared with first-generation agents, second-generation antiepileptics have a lower
propensity to cause PK DIs. To our knowledge, no systematic study has documented the effect of
newer antiepileptics on the disposition of antidepressants. Baird [83] described a case of a possible
clomipramine induction by oxcarbazepine.
3.1.2 Effect of antidepressants on the PKs of antiepileptics
Older antidepressants
While some antiepileptics can profoundly affect TCA plasma concentration, there is little
evidence that TCAs can influence the pharmacokinetics of anticonvulsants. One study showed that
nortriptyline coadministration produced a small increase in phenytoin levels [34], while in another
report plasma phenytoin concentration was found to increase in two patients during treatment with
imipramine and to return to baseline after its discontinuation [34].

Newer antidepressants
Fluoxetine and its metabolite norfluoxetine are potent inhibitors of CYP2D6 and moderate
inhibitors of CYP2C9, while they mildly to moderately affect the activity of CYP2C19 and
CYP3A4 31, 84. Case reports indicated that concurrent use of fluoxetine and phenytoin can result
in significantly increased phenytoin serum levels leading to toxicity [85-87]. This DI has been
attributed to the moderate inhibitory effect of fluoxetine on the CYP2C9-mediated
biotransformation of phenytoin [88]. Fluoxetine may also impair the elimination of carbamazepine,
as documented by case reports after the addition of fluoxetine [89, 90]. Conversely, no changes in
steady-state carbamazepine levels were observed in eight epileptic patients on a chronic treatment
with carbamazepine (800-1600 mg/day) after a 3-week coadministration with fluoxetine, 20
mg/day, suggesting that inhibition of CYP3A4-mediated carbamazepine metabolism might occur
only at higher fluoxetine doses [91] or require more than 3 weeks to manifest, due to the long halflife of norfluoxetine. Early case reports had documented that the addition of fluoxetine to an
ongoing treatment with valproic acid may increase steady-state plasma concentrations of valproic
acid, along with showing signs of toxicity [92-94]. The most plausible explanation for the raised
valproic acid levels is inhibition of CYP2C9 by fluoxetine. In a large routine TDM program for
lamotrigine, dose-normalized serum concentrations of lamotrigine were significantly lower (by
39%) in 15 patients taking fluoxetine than in the reference group of 224 subjects on lamotrigine
alone [95]. As fluoxetine is not a known enzyme inducer, but is a potent inhibitor of CYP enzymes,
the authors speculate that fluoxetine or its metabolite norfluoxetine may induce the UGT enzymes
involved in the glucuronidation of lamotrigine.
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Paroxetine is a potent inhibitor of CYP2D6, while it only minimally affects other CYPs 31,
84. In a single-blind, placebo-controlled, cross-over study of 20 patients with epilepsy, stabilized
on phenytoin, carbamazepine or valproic acid, addition of paroxetine, 10-30 mg/day for 16 days,
caused no significant changes in plasma concentrations of these antiepileptic drugs [61].
Fluvoxamine influences the activity of various CYP isoenzymes; it is a potent inhibitor of
CYP1A2 and CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4, while it affects
CYP2D6 activity only slightly 31, 84. Being an inhibitor of different CYP isoforms, fluvoxamine
may impair the elimination of various antiepileptics. There is conflicting evidence for a metabolic
DI between fluvoxamine and carbamazepine. Although case reports have documented that
fluvoxamine increased carbamazepine levels with associated symptoms of carbamazepine toxicity
[96, 97], one study of seven epileptic patients stabilized on carbamazepine (800-1600 mg/day)
found no such increase in carbamazepine levels after three weeks of coadministration with
fluvoxamine, 100 mg/day [91]. A case report documented a 3-fold increase in serum concentrations
of phenytoin after administration of fluvoxamine [98]. This pharmacokinetic change was explained
as a result of inhibition of both CYP2C9 and CYP2C19 by fluvoxamine.
Sertraline is a mild to moderate in vitro inhibitor of CYP2D6 and a weak inhibitor of the
other CYP isoenzymes 31, 84. Two RCTs, using double-blinding and placebo in healthy
volunteers, have documented that sertraline, at a dose of 200 mg/day for 17 days, did not affect the
pharmacokinetics of carbamazepine (400 mg/day for 32 days; n =14) and phenytoin (300 mg/day
for 24 days; n = 30), substrates for CYP3A4 and CYP2C9, respectively [99, 100]. On the other
hand, in a patient with bipolar depression treated with valproate, the addition of sertraline (100
mg/day) resulted in a 3-fold elevation in serum valproic acid concentration associated with signs of
valproate intoxication [101]. A clinically relevant PK DI may also occur between sertraline and
lamotrigine, a new antiepileptic which is predominantly metabolized by glucuronide conjugation. A
two-fold increase in plasma lamotrigine concentration associated with symptoms of toxicity was
observed in two epileptic patients 6 weeks after the addition of a low dose of sertraline, 25 mg/day
[102]. In a recent study aimed at evaluating the potential DI between sertraline and lamotrigine,
dose-corrected concentrations of lamotrigine were slightly, but not significantly, higher (by 18%) in
7 patients treated with both drugs in combination than in the 44 patients receiving only lamotrigine
[103].
Citalopram and its active S-enantiomer, escitalopram, are weak in vitro inhibitors of
CYP2D6 and are negligible inhibitors of CYP1A2, CYP2C9, CYP2C19 and CYP3A4 104, 105.
Due to their minimal effect on drug-metabolizing enzymes, citalopram and escitalopram are not
expected to cause clinically relevant DIs with antiepileptic drugs. In an open-label investigation in
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12 healthy volunteers, the addition of citalopram, 40 mg/day for 14 days, to carbamazepine,
administered at the dose of 400 mg/day for 35 days, did not alter the steady-state PK parameters of
carbamazepine and its active epoxide metabolite [106].
According to two investigations in healthy subjects, mirtazapine (30 mg/ day) had no effect
on PK parameters of both carbamazepine and phenytoin [65, 66].
Anecdotal evidence indicates that bupropion may inhibit the metabolism of phenytoin and
valproate [107]. On the other hand, in a randomized, open-label, two-way crossover study in 12
healthy subjects, PK parameters of a single oral dose of 100 mg lamotrigine were not affected by
steady-state bupropion, 150 mg twice/day [108].
3.2 PD DIs
3.2.1. PD DIs that increase efficacy
Pharmacodynamic drug interactions are rarely systematically studied, but there is some
limited literature supporting the theory that the combination of antiepileptic-antidepressants may
have additive and/or synergistic effects for treatment-resistant depression, anxiety, pain, migraine
prophylaxis and weight loss.
There are a few studies on the possible role of some antiepileptics for potentiating
antidepressants in major depressive disorder. They provide suggestive evidence of the beneficial
effects of adjunctive carbamazepine, lamotrigine, and valproate, particularly in patients taking
antidepressants for recurring major depressive disorder with prominent irritability or agitation [109]
but augmentation strategies, including lithium and antipsychotics, are usually preferred [110].
Pregabalin has been approved for generalized anxiety disorder in Europe. A RCT indicated
that adjunctive therapy with pregabalin in patients with a partial response to antidepressants in
generalized anxiety disorder was more effective than placebo [20] and this augmentation strategy is
recommended by a recent guideline [111].
Different antiepileptics and antidepressants are used as alternatives to analgesic opioids for
the treatment of chronic pain including fibromyalgia, painful diabetic neuropathy, postherpetic
neuralgia, neuropathic pain and painful neuropathy [112; Figures 3 and 5]. Clinicians and some of
the pain guidelines [112] recommend combinations of antiepileptics and antidepressants, as they
may work using different analgesic mechanisms. The number of RCTs demonstrating greater
efficacy of the antiepileptic-antidepressant combinations than the individual drugs is limited and
includes the combination of nortriptyline and gabapentin for neuropathic pain [113], and low-dose
pregabalin and low-dose antidepressants as adjunctive to opioids for intractable painful bone
metastasis [114].
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For migraine prophylaxis, meta-analyses support the efficacy of approved drugs including
topiramate and valproate [115, 116] and off-label TCAs, particularly amitriptyline [115, 117].
There is limited evidence for the use of some other antidepressants, including venlafaxine [115], but
clomipramine is considered ineffective in migraine prophylaxis [23]. Guidelines do not comment
on drug combinations for migraine prophylaxis [23], but clinicians use them. A recent RCT
obtained a response of 37% in monotherapy versus 78% in the combination of topiramate and
nortriptyline [118].
Both bupropion and zonisamide have been associated with weight loss but probably have
different mechanisms of action (Figures 3 and 5). An article reviewing RCTs using this
combination suggested that the combination may have additive effects [119], but the RCTs have not
yet been published.
Some articles implied the possibility of additive- and/or synergistic-type PD DIs between
antiepileptics and antidepressants for two unapproved indications: menopausal vasomotor
symptoms (Figures 2 and 4) and treatment-resistant OCD.
Hormonal replacement has been the treatment of menopausal hot flashes but there is
increased concern about its risk, leading to an increased use of non-hormonal therapies for
vasomotor symptoms (hot flashes and night sweats) in patients with natural or iatrogenicallyinduced menopause. Gabapentin and some antidepressants, SSRIs and SNRIs, have been studied
and appear to be better than placebo for menopausal symptoms (Figure 2 and 4). No RCT with
combined treatment has been published and a recent cross-over RCT [120] does not address the
combined effects.
There are few RCTs with antiepileptics in OCD, but one [121] suggests that lamotrigine
may potentiate the effects of serotonergic reuptake inhibitors in treatment-resistant OCD, possibly
due to its glutamatergic effects. A recent guideline recommended SSRI augmentation with
lamotrigine or topiramate as one of the options after initial SSRI non-response in OCD [111].
3.2.2. PD DIs that decrease efficacy
The literature provides some support for an antagonistic PD DI for antidepressants in bipolar
disorder maintenance. There is very limited RCT data on maintenance treatment after bipolar
depression [122], but there is general agreement that some antidepressants may increase the switch
to mania, whereas bupropion and SSRIs may have fewer risks than TCAs and SNRIs [123]. A
meta-analysis suggested that mood stabilizers may not prevent the switch to mania induced by
antidepressants, but too few studies have been conducted to establish certainty [124]. Future studies
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will need to verify whether or not antidepressants decrease the mood-stabilizing properties of mood
stabilizers by increasing mania-switching [125].
Figure 3 indicates depression is considered a common ADR to phenobarbital, primidone,
topiramate and vigabatrin. These antiepileptics should be used very cautiously in patients with a
history of depression. Other antiepileptics associated with depression, but less frequently, are
felbamate, levetiracetam, tiagabine and zonisamide. Although there are no studies supporting this, it
is pharmacologically reasonable to think that any of these antiepileptics can decrease or eliminate
the antidepressant effects in patients taking antidepressants.
Figure 5 indicates that bupropion and TCAs can decrease the seizure threshold and, as a
matter of fact, they have been associated with seizures in patients without history of epilepsy [126].
A meta-analysis of RCTs suggested that other newer antidepressants, which were combined in the
same group for statistical analysis, appeared to have less seizure risk than placebo [127]. Fluoxetine
animal studies suggest that it may have anti-seizure activity and can potentiate valproate
anticonvulsant effects [128]. In summary, bupropion and TCAs (maprotiline may be the worst)
should not be prescribed to epileptic patients with poor seizure control, since they can decrease the
efficacy of antiepileptics.
3.2.3. PD DIs that increase safety
Topiramate and zonisamide can decrease weight when taken with antidepressants associated
with weight gain (amitriptyline, mirtazapine, paroxetine) but there are no published studies.
Bupropion can decrease weight when taken with antiepileptics associated with weight gain but, as
previously described, it had the potential of decreasing the seizure threshold.
Antiepileptics in some peculiar circumstances may decrease the risk of arrhythmias
associated with antidepressants. Phenytoin may have beneficial effects on TCA overdoses [129].
Rufinamide is an unusual drug in the sense that it has been definitively associated with dosedependent reduction of QT interval [130] and has the potential to decrease QTc prolongations in
patients with SSRI-induced QT prolongations.
3.2.4. PD DIs that decrease safety
Non-studied PD DIs possibly associated with specific antidepressant compounds in
combination with antiepileptics may include increased risk for sedation, weight gain and metabolicassociated symptoms, nausea and urinary symptoms.
Sedation is a very common ADR for antiepileptics (except for felbamate, lacosamide,
lamotrigine and tiagabine, which may have a frequency <10% in RCTs). Antidepressants with
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clinically relevant antagonism of histamine 1 (H1) receptors including TCAs, trazodone and
mirtazapine are likely to increase the risk of sedation in patients taking antiepileptics; therefore,
prescribers may want to consider other antidepressants in patients taking antiepileptics.
The compounds associated with weight gain include among antiepileptics, carbamazepine,
gabapentin, pregabalin, retigabine, and valproate, and among antidepressants [49], some TCAs,
mirtazapine and paroxetine [131]. Therefore, the combination of any of these antiepileptics
associated with weight gain may have additive effects. The only antidepressant clearly associated
with hyperlipidemias is mirtazapine [132]. It should be cautiously added to potent inducer
antiepileptics that have been associated with hyperlipidemias (carbamazepine, phenobarbital,
phenytoin, and primidone; Figure 1).
Nausea and vomiting are common ADRs in almost all antiepileptics [133, 134] and are also
common for SSRIs and SNRIs [135]. Although there are no published articles addressing this issue,
it is not surprising that there are increased risks for nausea if antiepileptics are combined with
SSRIs or SNRIs. TCAs [136] and mirtazapine [137] have occasionally been used as antiemetics.
Retigabine can cause urinary retention due to its interference with bladder voltagedependent potassium channels [138]. It should be very cautiously combined with antidepressants
associated with urinary retention, including more potent antimuscarinic antidepressants (most
TCAs, mirtazapine and paroxetine), reboxetine and SNRIs (Figure 4).
Less common PD DIs possibly associated with combinations of antiepileptics and
antidepressants may include increased risk for lethal ADRs including hyponatremia, arrhythmias,
hepatotoxicity, hemorrhages and heat stroke.
Many antidepressants [139] and two antiepileptics [140], oxcarbazepine and carbamazepine,
appear to be consistently associated with hyponatremia, probably mediated by increasing
antidiuretic hormone (ADH) release and/or action. Clinical manifestations are relatively uncommon
and are more frequent in elderly females [139]. Recent larger hyponatremia studies [141] did not
explore the possibility that combinations of an antidepressant with one of these antiepileptics may
be more prone to cause symptomatic hyponatremia that the individual drugs.
Lethal arrhythmias are very complicated to study since these deaths are relatively rare and
are not easily identified in autopsies. Several syndromes are associated with sudden cardiac death.
One of them is Brugada syndrome (see footnote 7 of Figure 3), which has been linked with newer
antidepressants (Figure 5) and some antiepileptics (Figure 3) [142]. Obviously, the listed
antiepileptics and antidepressants should be avoided in these patients and never combined.
Several antidepressants have been associated with torsades de pointes including citalopram,
fluoxetine and sertraline (Figure 5) [143, 144]. They should not be combined with felbamate, which
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has also been associated with torsades de pointes, or with retigabine, which has been associated
with QTc prolongations (Figure 3).
Agomelatine has been definitively associated with liver enzyme elevations. Most cases
(90%) recover after agomelatine discontinuation but severe forms can also occur [145].
Agomelatine should be very carefully prescribed when started in any patients using antiepileptics
with greater risk of hepatotoxicity including carbamazepine, felbamate, phenytoin and valproate. In
their recent review, Voican et al. [146] stated that, besides agomelatine, bupropion, duloxetine,
TCAs and trazodone are the most frequent antidepressants that, on rare occasions, can cause lifethreatening hepatotoxicity. They suggest that these antidepressants should not be administered in
those with prior liver problems. Therefore, we propose that bupropion, duloxetine, TCAs and
trazodone should not be used in those with prior history of liver injury secondary to antiepileptics,
or with current liver enzyme elevations during antiepileptic treatment.
Figure 5 indicates that epidemiological studies definitively establish SSRIs as producing a
small increased risk for abnormal bleeding by depleting platelets from serotonin, particularly when
other risk factors are present, such as some drugs or surgery [147]. Valproate causes a common
dose-related thrombocytopenia and on rare occasions interferes with the coagulation system [148;
Figure 3] and may increase the risk of SSRI-induced bleeding, but this DI has not been studied.
Topiramate and zonisamide are inhibitors of carbonic anhydrase, decreasing the ability to
produce sweat. Antimuscarinic drugs such as TCAs and mirtazapine can also cause hypohidrosis
[149]. Combinations of topiramate or zonisamide with most potent antimuscarinic antidepressants
should be avoided during hot summers, particularly in the elderly, or in patients exposed to
strenuous exercise.
Suicide and osteoporosis are two possible ADRs that have been associated with
antiepileptics and antidepressants, but the connections are not definitively established due to the
difficulty of studying them. If these associations are not spurious, the combinations of these drugs
may increase the risk.
After meta-analyses, the US Food and Drug Administration (FDA) issued separate warnings
of suicidality with antidepressants and antiepileptics. The risk of suicidality on antidepressants
decreased and the benefits increased with age. There was a significant twofold risk of suicidality
among children and adolescents randomized to antidepressants; whereas there was a statistically
significant protective effect of antidepressants among those 65 and older [150]. Risk of suicidality,
mainly suicidal ideation, was significantly elevated among subjects randomized to receive an
antiepileptic, compared with placebo [151]. As these warnings come from studies in which it is not
easy to eliminate confounders, including the presence of psychiatric disorders, the warnings are
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considered controversial by many clinicians. The literature does not comment on the possibility of
the increased risk of suicide in combining antiepileptics and antidepressants. Leon et al., [152]
using a sophisticated statistical approach to analyze observational studies, concluded that the risk of
suicide attempts or suicides was significantly reduced when the participants received
antidepressants. However, there was neither significant risk nor protection from suicidality among
participants receiving antiepileptics.
Strong inducer antiepileptics are definitively associated with osteoporosis (Figure 1) and
epidemiological studies [153] are starting to suggest that SSRIs may also be associated with
increased risk for osteoporosis (Figure 4). Although it has not been studied, they may potentiate
each other’s effects on osteoporosis.

4. Conclusion
This section and Table 4 provide a summary of the most important practical DI information
for clinicians.
4.1 PK DIs and clinical implications
Carbamazepine, phenobarbital, phenytoin and primidone are potent inducers that are likely
to have clinically relevant effects on several antidepressant levels (Table 3). Adding any of these
inducers (in the absence of other inducers) may be associated with a decrease in antidepressant
plasma concentration that may be associated with lack of efficacy. The discontinuation of these
inducers (when other inducers are not prescribed) may be associated with an increase in plasma
antidepressant concentration that may be associated with ADRs. As antidepressant TDM may not
be developed for some new antidepressants or clinicians may not have access to it in their clinical
practices, Table 4 provides estimates for correction factors based on the limited available literature.
A major problem is the absence of studies of the effect of potent inducers with agomelatine,
desvenlafaxine, duloxetine, escitalopram, levomilnacipran, reboxetine, sertraline, venlafaxine,
vilazodone, and vortioxetine. Antidepressants mainly dependent for their metabolism on CYP3A4
such as reboxetine or vilazodone may be particularly sensitive to induction. According to data from
antipsychotics dependent on CYP3A4, they may require a correction factor of at least 5 [28].
The pharmacokinetic DIs associated with mild CYP3A4 inducers, such as clobazam,
eslicarbazepine, oxcarbazepine, rufinamide and topiramate (Table 4), are not likely to be clinically
relevant in most patients taking antidepressants, but it cannot be ruled out that in some unusual
patients they may have clinical relevance. In that sense, clinicians may need to be watchful when
using high doses of oxcarbazepine (≥ 1200 mg/day) or topiramate (≥ 400 mg/day), particularly with
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antidepressants that require important dose corrections, when using potent inducers such as
mirtazapine and TCAs, or those mainly metabolized by CYP3A4 such as reboxetine or vilazodone.
Antidepressant DI studies should consider that valproic acid may not be an inhibitor of some
metabolic enzymes, but a mild inducer of other metabolic enzymes or transporters, or behave both
as a mild inducer and a competitive inhibitor [70].
Fluoxetine and fluvoxamine are relevant inhibitors of phenytoin and valproic acid, but the
literature does not provide information on calculating dose correction factors. Therefore, fluoxetine
and fluvoxamine should not be added or discontinued from patients taking phenytoin or valproic
acid without close monitoring of the antiepileptic TDM. Other not-well-studied antiepileptics likely
to be influenced by the inhibitory effects of fluoxetine or fluvoxamine are those dependent on
CYP2C9 or CYP2C19 for their metabolism, including clobazam, lacosamide, phenobarbital, or
primidone. Fluoxetine may take up to 2-3 months in an average patient (or even up to 6 months in
unusual patients) to reach maximal inhibitory effects on CYP3A4 due to the long half-life of
norfluoxetine, so it may be important to remember that when co-prescribing fluoxetine with
antiepileptics dependent on CYP3A4 such as carbamazepine, felbamate, tiagabine, or zonisamide.
Table 4 reports that it may be safer to select antidepressants other than fluoxetine or fluvoxamine
when taking any of these antiepileptics. Isolated cases have suggested that it may be safer to avoid
fluoxetine and sertraline in patients taking lamotrigine (Table 4). Studies of high doses of sertraline
should rule out that it inhibits valproate and/or lamotrigine metabolism. In vitro studies suggest that
TCAs (Table 2) are moderate CYP2C19 inhibitors; therefore, TCAs have potential for inhibiting
the metabolism of some antiepileptics including lacosamide and clobazam’s main metabolite.
4.2 PD DIs and clinical implications
In our experience, pharmacodynamic DIs are very relevant in clinical practice (Table 4).
Five unstudied pharmacodynamic DIs may prove beneficial by increasing efficacy (Table 4): i) the
possible additive effects for generalized anxiety disorder when adding pregabalin to an
antidepressant, ii) the possible additive effects for chronic pain when combining some antiepileptics
(carbamazepine, gabapentin, oxcarbazepine, or pregabalin) with SNRIs or TCAs, iii) the possible
additive effects for migraine prophylaxis when combining topiramate or valproic acid with TCAs
(particularly amitriptyline) or venlafaxine, iv) the possible additive effects for weight control when
combining bupropion and zonisamide (or topiramate), and v) the possible additive effects for
menopausal symptoms when combining gabapentin with SNRIs or SSRIs.
Two pharmacodynamic DIs may cause harm by decreasing efficacy (Table 4): i) some
antiepileptics, (Table 4) particularly phenobarbital, primidone, topiramate, and vigabatrin have
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been associated with depression and should be avoided in patients with that vulnerability; and ii)
bupropion and TCAs should be avoided in patients with epilepsy due to the risk of decreasing the
seizure threshold. The controversial issue of adding antidepressants for bipolar depression has been
described in Section 3.2.2.
Two unstudied PD DIs have the potential to be beneficial by increasing safety (Table 4): i)
topiramate and zonisamide may decrease the effect on weight of antidepressants associated with
weight gain (amitriptyline, mirtazapine, paroxetine), and ii) rufinamide may decrease QTc in
patients with SSRIs. Fluoxetine has been associated with in vitro effects of anticonvulsant
properties but has major potential for pharmacokinetic DIs. It is not clear whether other SSRIs share
those anticonvulsant properties. Bupropion and TCAs clearly decrease the seizure threshold.
Five additive (or synergistic) DIs with increased risk for common ADRs include increased
risk for sedation, weight gain, hyperlipidemia, nausea, and urinary retention. Table 4 describes the
specific combinations, along with these increased safely risks. Finally, Table 4 describes five
potentially lethal PD DIs: hyponatremia, torsades de pointes, hepatic failure, hemorrhages, and heat
stroke. These ADRs are very rare and we are not sure that antiepileptic-antidepressant combinations
increase their risk but pharmacological mechanisms suggest that possibility, and clinicians need to
remember the potential for PD Dis in order to prevent or quickly diagnose them.
Finally, long-term treatment with antiepileptics that are potent inducers is definitively
associated with osteoporosis.

Recent studies, which may take many years for definitive

confirmation, suggest that mild inducers, such as oxcarbazepine, topiramate or valproic acid, and
SSRIs may be associated with osteoporosis. Clinicians may want to consider the possible increased
risks when combining SSRIs with these mild inducers over many years.

5. Expert opinion
The pharmacological mechanisms and clinical relevance of DIs associated with the
inductive properties of carbamazepine, phenytoin, phenobarbital and primidone and the inhibitory
properties of valproate and some antidepressants are well understood while pharmacokinetic DI
studies with new antiepileptics and new antidepressants are limited. It appears safer to overwarn
clinicians about the potential risks of losing efficacy when adding inducers or of increased ADRs
when adding inhibitors, as well as the risks of ADRs when discontinuing inducers or losing efficacy
when discontinuing inhibitors. Clinicians cannot afford to wait for definitive studies, which are not
likely to happen once the new drugs are already marketed. Table 4 provides correction factors
calculated using the available PK studies, assuming that the average patient represents the
population well. However, there is extensive PK variability among patients, and TDM
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measurements should be advised for optimal titration of the dosage in each individual. These
limited correction factors are useful because: i) many clinicians have no access to TDM; ii) there is
limited clinical data on TDM for new compounds; and iii) having the correction factor helps
clinicians to make decisions to use safer drugs. With a correction factor of 10, bupropion is a very
poor antidepressant choice for patients taking antiepileptics with powerful inductive properties.
There will be a need to periodically update these correction factors as new knowledge becomes
available.
Using the limited available information, the authors believe that in high doses oxcarbazepine
(≥ 1200 mg/day) and topiramate (≥ 400 mg/day) may be clinically relevant CYP3A4 inducers and
possible inducers of some UGTs. It is possible that clobazam, eslicarbazepine, and rufinamide may
also be dose-dependent CYP3A4 inducers. Two other mild inducers, felbamate and vigabatrin, are
rarely prescribed. More problematic is the case of valproic acid, a drug traditionally considered a
potential inhibitor, which may also be a dose-dependent mild inducer of some antipsychotics. The
metabolic enzymes and/or transporters influenced by valproic acid induction are not known. These
metabolic enzymes and/or transporters may also be subject to competitive inhibition by valproic
acid [70]. As described earlier, valproic acid may also a vitamin D inducer [45].
It is not easy to conduct DI studies using clinically relevant doses of inducers or inhibitors.
Pharmaceutical companies tend to invest in simple PK DI studies in volunteers, frequently using
single dosing to get approval for the marketing of their drugs, but this type of PK study rarely
reflects clinical practice. The DI material in prescribing information (or package inserts) is usually
not designed to provide easy helps for clinicians to correct PK DIs with dose changes. It appears
naïve to criticize the PK science on antiepileptic-antidepressant combinations; at least there is some
PK data. There is almost no PD science on antiepileptic-antidepressant combinations. The potential
PD DIs described in Table 4 were developed after reviewing known pharmacological mechanisms,
efficacy and ADRs in antiepileptic or antidepressant studies. There are almost no studies of the
potential synergistic or additive benefits of combining antiepileptics and antidepressants for
generalized anxiety disorder, pain, migraine prophylaxis, weight and menopausal symptoms. The
lack of studies in OCD is an even more problematic case. Some studies have used adjuvant
antiepileptics such as lamotrigine for patients who did not sufficiently respond to SSRIs [121].
OCD guidelines usually recommend SSRIs as first-line, followed by augmentation with
clomipramine and/or antipsychotics, but there is no information for clinicians on what to do when
all three treatments have been tried. Patients resistant to these three steps are usually very impaired
and not likely to recover spontaneously, or have placebo response [154]. It would be ideal to
complete RCTs with adjunctive treatment with lamotrigine or topiramate, but the great severity of
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this type of treatment-refractory patients make them unlikely to take part in RCTs. This is a good
example of a generalized problem in clinical practice: the more difficult the patient, the less
information is available to guide the treatment. In difficult patients, clinicians frequently use drug
combinations in the absence of good information on their risk/benefit; moreover, they prefer
combinations to monotherapy.
Clinicians use antiepileptic-antidepressant combinations frequently in patients for anxiety
disorder, pain, migraine prophylaxis, weight and menopausal symptoms, looking for greater
efficacy, and for depression in the presence of any primary indications for antiepileptics such as
epilepsy. There is obviously more need for studies of PK and PD DI between antiepileptics and
antidepressants, but the lack of funding for clinical research is a major limitation. Collaboration
from all interested parties is needed, including: i) drug agencies and pharmaceutical companies; ii)
clinicians using antiepileptic-antidepressant combinations; iii) researchers with expertise in a) metaanalyses, b) pharmacoepidemiology, and c) DI pharmacology; and iv) grant agencies.
Drug agencies should be more insistent upon rapid approval for new antiepileptics with PD
mechanisms analogous to those from already-approved compounds and with less risk for PK DIs.
Oxcarbazepine and eslicarbazepine are likely to have efficacy in the same disorders as
carbamazepine. It may be a good idea for drug agencies to facilitate and simplify an efficacy study
as a long-term PK study with high doses and enough time duration to establish the real potential for
induction of these compounds. There are analogs of valproic acid in development for epilepsy but it
will be important to establish that they have better pharmacokinetic DIs and less toxicity than
valproic acid for non-epileptic indications.
There is great need for naturalistic studies by clinicians describing the possible additive or
synergistic effects related to the efficacy and safety of the antiepileptic-antidepressant
combinations. Are early sedation or early nausea and vomiting more frequent in some of these
combinations than in the various monotherapies? Is osteoporosis a long-term issue in vulnerable
patients taking mild antiepileptic inducers and SSRIs for years?
Researchers with expertise in meta-analysis may need to be ready to analyze the efficacy
and safety of antiepileptic-antidepressant combinations, comparing them to studies of the drugs
individually. Researchers with expertise in pharmacoepidemiology need to explore whether rare,
but potentially lethal, ADRs such as hyponatremia, torsades de pointes, hepatic failure;
hemorrhages, and heat stroke may be more frequently associated with using antiepilepticantidepressant combinations than with individual drugs. Researchers with expertise in in vitro DI
studies or in vivo clinical studies using isotopes to explore drug clearance need to better study the
new antiepileptics’ and the new antidepressants’ metabolic pathways and how they change when
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inhibitors, such as valproic acid or SSRIs, and inducers, such as high doses of mild inducers, are
added.
Grant and health agencies need to remember that pragmatic clinical trials are key in treating
complex disorders such as epilepsy, bipolar disorder, chronic pain or in preventing migraines where
polytherapy is the norm. Pharmaceutical RCTs do not substitute for long-term pragmatic trials that
may better inform clinicians of the effectiveness of the various types of mono- and polytherapy
frequently used in the real world of clinical practice. Pragmatic trials need to pay better attention to
DIs.
Knowledge of DIs is becoming more complex, since even antiepileptic mild inducers may
have clinically relevant PK DIs. Progress in the next few years may not be guaranteed even if this
ambitious research agenda is followed, unless it is accompanied by a better continuous medical
education concerning DIs and improvements in neuropsychopharmacology textbooks, so that
clinicians begin to pay more attention to PD and PK DIs associated with the frequent coprescription of antiepileptic-antidepressant combinations. The authors would like to see welleducated clinicians assist in pushing this research agenda forward by publishing DI case reports of
unusual combinations and asking for more DI studies from pharmaceutical companies and
researchers.
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Table 1. Pharmacokinetic parameters of antiepileptics. Based on [28, 37].

Bioavail
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75-85
Carbamazepine

Protein
binding
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Halflife (h)

Most important
way of
elimination1

Other ways of elimination

Active metabolites

Induction or
inhibition of
metabolic enzymes

Carbamazepine
epoxide

Induction of CYP1A2,
CYP2A6, CYP2B6,
CYP2C9, CYP2C19,
CYP3A4, UGT1A1,
UGT2B7, UGT2B15,
epoxide hydrolase

75

5-26

CYP3A42

CYP2C8, CYP1A2,
UGT2B7, epoxide hydrolase

Ethosuximide
Phenytoin

90-100
90

<10
90

25-70
7-80

CYP3A42
CYP2C92

CYP2E1, renal
CYP2C19 (less important:
CYP2C18, CYP3A4)

Phenobarbital

>95

45-60

70-130

CYP2C92

CYP2C19, CYP2E1,
N-glucosidation, renal

Primidone

>90

10

5-20

CYP2C92

Renal, CYP2C19, CYP2E1,
N-glucosidation,

Valproate

>90

70-95

8-16

Several UGTs

-oxidation, CYP2C9 (other
CYPs are minor)

Phenobarbital

Induction of CYP1A2,
CYP2B6, CYP2C8,
CYP2C9, CYP2C19,
CYP3A4, UGTs,
epoxide hydrolase
Induction of CYP1A2,
CYP2B6, CYP2C8,
CYP2C9, CYP2C19,
CYP2E1, CYP3A4,
UGT, epoxide
hydrolase
Induction of CYP1A2,
CYP2B6, CYP2C8,
CYP2C9, CYP2C19,
CYP2E1, CYP3A4,
UGT, epoxide
hydrolase
Inhibition of CYP2C9,
UGT1A4, UGT2B7,
epoxide hydrolase, Nglucosidation.
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Mild auto-induction3
and mild induction of
other drugs3
SECOND GENERATION
Clobazam
100

Eslicarbazepine

Felbamate

100

90

80-90

30

20-25

36-42

13-20

11-25

CYP3A42

UGTs5

CYP3A42

CYP2C194

Renal

Ndesmethylclobazam

S-licarbazepine

Mild induction of
CYP3A4
Mild inhibition of
CYP2C19 and
CYP2D6
Mild induction of
CYP3A4, UGTs.
Mild inhibition of
CYP2C9, CYP2C19
Mild induction of
CYP3A4

Renal, CYP2E1, UGTs

Inhibition of
CYP2C19, oxidation
Gabapentin
Lacosamide
Lamotrigine

<65
100
>95

0
<15
55

5-9
12-16
25

Renal
CYP2C192
UGT1A4

Renal

Levetiracetam
Oxcarbazepine

100
100

<10
40

6-8
7-12

Renal
Renal

Esterase hydrolysis in blood
UGTs

Mild induction of
UGTs.
MHD
(monohydroxy
derivate) 6

Mild induction of
CYP3A4, UGTs
Mild inhibition of
CYP2C19.

Pregabalin
Retigabine
(ezogabine)

>90
60

0
80

5-7
8-10

Rufinamide

85

30

8-12

Renal
Arylamine Nacetyl
transferase-2
Carboxylesterases

UGTs
Mild induction of
CYP3A4, UGTs
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Stiripentol

>70

99

4.5-13

Tiagabine
Topiramate

100
100

96
13-17

5-9
10-30

Vigabatrin

>50

0

100

50

4-7

CYP1A2, CYP2C19,
CYP3A4, UGTs7
CYP3A42
Renal

Renal
CYP3A42

CYP

CYP (only 10%)

Mild inhibition of
CYP2E1.
Inhibition of CYP1A2,
CYP2C19, CYP2D6,
CYP3A4.
Mild induction of
CYP3A4, -oxidation,
UGT1A4.
Mild inhibition of
CYP2C19.
Mild induction of
CYP2C9.

N-acetylation transferase,
renal
CYP: cytochrome P450; UGT: uridine diphosphate glucuronosyltransferase
1
This refers to normal metabolism. Some subjects may not have this enzyme or have it inhibited. Other enzymes may become more important during induction.
2
Any substrate competes with others for the corresponding enzyme and inhibits it (competitive inhibition). There is data in the literature that competitive
inhibition may occur at CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. UGTs tend to have overlapping substrates and it is not clear that they can be
subject to competitive inhibition. A good example of competitive inhibition is phenytoin in high serum concentrations (>20 mcg/ml) which may saturate
completely or almost completely its metabolic enzymes, CYP2C9 and CYP2C19.
3
Valproate has been demonstrated to have mild-autoinduction properties by inducing β-oxidation. Valproate may be an inducer of the metabolism of other
medications including aripiprazole, clozapine, irinotecan and olanzapine but the induced enzymes are not established.
4
N-desmethlyclobazam is mainly metabolized by CYP2C19.
5
Eslicarbazepine is a pro-drug that is activated by hepatic esterases to S-licarbazepine. S-licarbazepine is eliminated by UGTs and by the kidney (unchanged).
6
MHD is also called licarbazepine. Oxcarbazepine is a pro-drug and is activated by a cytosolic arylketone reductase that converts it to MHD, the active drug.
7
There are four metabolic pathways. No specific enzyme can be considered a major enzyme.

Zonisamide

50-70
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Table 2. Pharmacokinetic parameters of antidepressants. Based on [29, 31-33, 39].

Bioavailability
(%)

Protein
binding
(%)

Half-life (h)

Most
important way
of elimination1

Other ways of
elimination

Active metabolites

TCA
Amitriptyline

30-60

96

10-50

50

97-98

19-37

Imipramine
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60-95

8-20

CYP1A2, CYP2C9,
CYP3A4
CYP1A2, CYP2C9,
CYP3A4
CYP1A2, CYP2C9,
CYP3A4

Nortriptyline

Clomipramine

Nortriptyline
SSRI
Citalopram
Escitalopram
Fluoxetine

51

93

16-38

CYP2C19 and
CYP2D62
CYP2C19 and
CYP2D62
CYP2C19 and
CYP2D62
CYP2D62

95
80
80

82
56
95

23-45
27
2-4 days

CYP2C192
CYP2C192
CYP2D62

CYP3A4, CYP2D6
CYP3A4, CYP2D6
CYP2C9, CYP2C19,
CYP3A4

Fluvoxamine

<53

77

15-22

CYP1A2,
CYP2D6

Paroxetine

>64

93

10-21

CYP2D62

CYP3A4

Sertraline

>44

98

22-36

CYP2B6

CYP2C19, CYP2C9,
CYP2D6, CYP3A4

SNRI

Inhibitory effect on CYP
isoenzymes

CYP2C19 (moderate)
CYP2D6 (weak)
Desmethylclomipramine CYP2C19 (moderate)
CYP2D6 (weak)
Desipramine
CYP2C19 (moderate)
CYP2D6 (weak)
CYP2D6 (weak)

Norfluoxetine

CYP2D6 (weak)
CYP2D6 (weak)
CYP2D6 (potent)
CYP2C9 (moderate)
CYP2C19 and CYP3A4
(weak to moderate)
CYP1A2 (weak)
CYP1A2 and CYP2C19
(potent)
CYP2C9 and CYP3A4
(moderate)
CYP2D6 (weak)
CYP2D6 (potent)
CYP1A2, CYP2C9,
CYP2C19, CYP3A4 (weak)
CYP2D6 (weak to
moderate)
CYP1A2, CYP2C9,
CYP2C19 and CYP3A4
(weak)
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Desvenlafaxine
Duloxetine
Levomilnacipran

80
50
92

30
>90
22

9-15
10-12
12

Renal
CYP1A22
Renal

UGT, CYP3A4
CYP2D6
UGT, CYP3A4

Milnacipran
Venlafaxine
Other newer
antidepressants
Agomelatine
Bupropion

85
92

13
27

8-10
5

Renal
CYP2D62

UGT, CYP3A4
CYP3A4

<5
90

95
84

1-2
20

CYP1A22
CYP2B6

CYP2C9

Mirtazapine

50

85

20-40

CYP1A2, UGTs

Reboxetine
Trazodone

>60
65

97
89-95

12-16
5-9

CYP2D6,
CYP3A4
CYP3A42
CYP3A42

723

96-99

20-24

CYP3A42

CYP2D6 (moderate)
CYP3A4 (weak)
Desvenlafaxine

Hydroxybupropion
Threohydrobupropion
Erythrohydrobupropion

CYP2D6 (moderate)

mchlorophenylpiperazine
(mCPP)

CYP2C19, CYP2D6,
CYP2C8 (?)
Carboxylesterase
CYP3A4, CYP2C19,
75
98
57-66
CYP2D62
Vortioxetine
CYP2C9, CYP2A6,
CYP2C8, CYP2B6
CYP: Cytochrome P450; SNRI: Serotonin and noradrenaline reuptake inhibitor; SSRI: Selective serotonin reuptake inhibitor; TCA; tricyclic
antidepressant; UGT: Uridine diphosphate glucuronosyltransferase.
1
This refers to normal metabolism. Some subjects may not have this enzyme or the enzyme is inhibited. Other enzymes may become more important during
induction.
2
Any substrate competes with others for the corresponding enzyme and inhibits it (competitive inhibition). Data in the literature shows that competitive inhibition
may occur at CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. UGTs tend to have overlapping substrates and it is not clear that they can be subject to
competitive inhibition. For example, venlafaxine can behave as a CYP2D6 competitive inhibitor.
3
Absorption is decreased when not administered with food.
Vilazodone
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Table 3. Summary of pharmacokinetic drug interactions between antiepileptics and antidepressants.
Antiepileptic

Antidepressant

Effect

Proposed mechanism

Carbamazepine

TCA

Decrease in plasma TCA concentrations (40-70%)

Fluoxetine

[89-91]

Induction of CYP (?)
Inhibition of CYP3A4 (?)

[60, 61]
[91, 96, 97]

Milnacipran

Minimal increase or no change in plasma concentrations of
carbamazepine
Decrease by 25% in plasma concentrations of paroxetine
Minimal increase or no change in plasma concentrations of
carbamazepine
Marked decrease in plasma sertraline concentrations in two patients
Decrease in plasma concentrations of S-citalopram and R-citalopram
by 27 and 31%
Decrease by 20% in plasma concentrations of milnacipran

Induction of various CYP
isoforms (CYP2C19,
CYP1A2 and CYP3A4)
Inhibition of CYP3A4 (?)

Phenobarbital

Mirtazapine
Bupropion
TCAs

Reduction by 39% in Cmax of mirtazapine and by 66% in its AUC
Decrease in the Cmax of bupropion by 87% and in its AUC by 90%
Decrease in plasma TCA concentrations (40-70%)

Phenytoin

TCAs

Decrease in TCA plasma concentrations (40-70%)

Fluoxetine
Fluvoxamine

Increase in plasma concentrations of phenytoin
A case report documented a 3-fold increase in serum concentrations of
phenytoin after administration of fluvoxamine
Reduction by 33% in Cmax of mirtazapine and by 47% in its AUC
50% to 60% elevation in plasma concentrations of amitriptyline and
nortriptyline

Paroxetine
Fluvoxamine
Sertraline
Citalopram

Valproic acid

Mirtazapine
Amitriptyline
Doxepin

Higher serum concentrations of doxepin plus N-doxepin (by 124%,
p<0.01) in patients comedicated with valproic acid

Fluoxetine
Venlafaxine

Increase in plasma concentrations of valproate
Serum concentrations of the active metabolite Odesmethylvenlafaxine were significantly higher (by 27%, p<0.02) in

References
[34]

Induction of CYP3A4
Induction of CYP3A4

[62]
[63]

Induction of CYP3A4 and
UGT
Induction of CYP3A4
Induction of CYP3A4
Induction of various CYP
isoforms (CYP2C19,
CYP1A2 and CYP3A4)
Induction of various CYP
isoforms (CYP2C19,
CYP1A2 and CYP3A4)
Inhibition of CYP2C9
Inhibition of both CYP2C9
and CYP2C19
Induction of CYP3A4
Inhibition of CYP2C9 and,
possibly CYP2C19 and
CYP3A4
Inhibition of CYP2C9 and,
possibly CYP2C19 and
CYP3A4
Inhibition of CYP2C9
Inhibition of CYP2C9

[64]
[65]
[67]
[34]
[34]

[88]
[98]
[66]
[71-73, 79]
[80]
[92-94]
[80]
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Lamotrigine

Fluoxetine
Sertraline

patients treated with the combination of valproic acid with
venlafaxine.
Lower serum concentrations of lamotrigine in patients comedicated
with fluoxetine
Slight increase (by 18%) in plasma concentrations of lamotrigine

Induction of UGT enzymes?

[99]

Inhibition of UGT2B7?

[103]

Cmax: Peak plasma concentration; AUC: Area under the plasma concentration-time curve; CYP: Cytochrome P450; TCA: tricyclic antidepressant. UGT: Uridine
diphosphate glucuronosyltransferase.
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Table 4. Practical summary of antiepileptic and antidepressant drug interactions
ANTIDEPRESSANTS
OUTCOME
ANTIEPILEPTICS
PK DI. Powerful inducers:
↓ antidepressant level 2-4 wks after
carbamazepine, phenobarbital Bupropion>2
adding inducer
phenytoin, primidone
↑ antidepressant level 2-4 wks after D/C
Inducer
Mirtazapine>
2
TCAs>
Citalopram, milnacipran, paroxetine

PK DI. Mild CYP3A4
inducers:3
Clobazam, eslicarbazepine,
felbamate, oxcarbazepine,
topiramate,
Rufinamide

PK DI. Phenytoin, valproate

Agomelatine, desvenlafaxine,
duloxetine, escitalopram,
levomilnacipran, reboxetine,
sertraline, venlafaxine, vilazodone,
vortioxetine
Fluoxetine, fluvoxamine
Possibly relevant for: bupropion,
mirtazapine, TCAs, reboxetine,
vilazodone

Fluoxetine, fluvoxamine

Not studied but likely to be
relevant: clobazam,
lacosamide, phenobarbital, or
primidone.
Not studied at steady state;
Fluoxetine
inhibitory effects of
fluoxetine: carbamazepine,
felbamate, tiagabine,
zonisamide
PK DI. Valproate

TCAs

PK DI. Lamotrigine

Fluoxetine, sertraline

Not relevant
↓ mild antidepressant level 2-4 wks after
adding mild inducer
↑ mild antidepressant level 2-4 wks after
D/C mild inducer

ACTIONS
In the absence of TDM, use correction factor:1
Better to avoid unless having extensive bupropion
TDM experience3
2-3
2 (1.4-2,5)4 Better using TCA TDM
1.3 If this correction factor is correct, it may not be
clinically relevant
Not studied
Be careful; induction of these antidepressants is
possible. Reboxetine and vilazodone (dependent on
CYP3A4 for their metabolism) may require high
correction factors: ≥5)
Possibly no clinically relevant changes
Monitor for ↓ efficacy after adding mild inducer.
Monitor for ADRs after discontinuing mild inducer

↑ antiepileptic level after adding inhibitor
↓ antiepileptic level after D/C inhibitor

Use antiepileptic TDM
It may be safer to select another antidepressant

↑ antiepileptic level 2-3 months after
adding fluoxetine in average patient (some
may take longer)
↓ antiepileptic level 2-3 months after
adding fluoxetine in average patient (some
may take longer)
↑ TCA level after adding valproate
↓ TCA level after D/C valproate
Some isolated cases suggest that
lamotrigine induction may be possible with
fluoxetine and lamotrigine inhibition may

Use antiepileptic TDM
It may be safer to select another antidepressant

Better using TCA TDM
Monitor for TCA ADRs
Be alert to the possibility that fluoxetine may ↓
lamotrigine levels while sertraline may ↑
lamotrigine level
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be possible with sertraline.
PD DI. Pregabalin

Antidepressants

PD DI. Carbamazepine,
gabapentin, oxcarbazepine,
pregabalin
PD DI. Topiramate, valproic
acid
PD DI. Zonisamide (possibly
topiramate)
PD DI. Gabapentin

SNRIs, TCAs
TCAs, particularly amitriptyline.
Possibly venlafaxine
Bupropion
SNRIs, SSRIs

May have additive effects for generalized
anxiety disorder (not well-studied)
May have additive effects for pain treatment
(not well-studied)
May have additive effects for migraine
treatment (not well-studied)
May have additive effects for weight
reduction (not well-studied)
May have additive effects for reducing
menopausal symptoms (not well-studied;
none of these drugs have been approved)
These antiepileptics have been associated
with depression

PD DI. Phenobarbital,
primidone, topiramate,
vigabatrin> zonisamide >
felbamate, levetiracetam,
tiagabine
PD DI. Antiepileptics for
epilepsy

Antidepressants

Bupropion, TCAs

These antidepressants have been associated
with ↑ risk for seizures

PD DI. Antiepileptics for
epilepsy

Fluoxetine (possible other SSRIs and
SNRIs)

PD DI. Topiramate,
zonisamide
PD DI. Rufinamide

Amitriptyline, mirtazapine, paroxetine
SSRIs

PD DI. Most antiepileptics

Mirtazapine, TCAs, and trazodone

Fluoxetine has displayed in vitro
antiepileptic properties in some models
Other SSRIs and SNRIs have been
associated with ↓ risk for seizures in metaanalyses but there are also case reports
associating them with seizures in patients
with no seizure history
These antiepileptics have been associated
with ↓ weight gain
Rufinamide has been associated with ↓ in
QTc
Additive sedation risk

PD DI. Carbamazepine,
gabapentin, pregabalin,
retigabine, valproate
PD DI. Carbamazepine,

Amitriptyline, mirtazapine, paroxetine
Mirtazapine

These antiepileptics and antidepressants
have been associated with ↑ weight gain and
may have additive effects.
These antiepileptics and mirtazapine have

Consider lamotrigine TDM before and after adding
fluoxetine or sertraline or select another
antidepressant
Be aware
Be aware
Be aware
Remember that valproic acid may ↑ TCA level
Be aware
Be aware
Avoid using them in patients taking antidepressants
for depression
If you use them, review PK DIs
Avoid using them in patients taking antiepileptics
for epilepsy
If you use them, review PK DIs
Consider them when needing antidepressant in
patients taking antiepileptics for not-well-controlled
epilepsy
If you decide to use fluoxetine, be very careful with
PK DIs
Be aware
If you use them, review other PK and PD DIs
Be aware
If you use them, review other PK and PD DIs
Be aware
Remember that felbamate, lacosamide, lamotrigine
and tiagabine are less sedating
Be aware
Be aware
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phenobarbital, phenytoin,
primidone
PD DI. Most antiepileptics

PD DI. Retigabine

PD DI. Oxcarbazepine>2
carbamazepine

PD DI. Felbamate, retigabine

SNRIs, SSRIs

Most TCAs>2 mirtazapine, paroxetine
due to antimuscarinic activity;
SNRIs and reboxetine probably due to
noradrenergic mechanisms
Probably all antidepressants

SSRIs (particularly citalopram,
fluoxetine and sertraline)

been associated with hyperlipidemia and
may have additive effects
Most antiepileptics and these
antidepressants have been associated with
nausea/vomiting and may have additive
effects
Retigabine and these antidepressants have
been associated with ↑ risk for urinary
retention
Oxcarbazepine and carbamazepine and
antidepressants have been associated with ↑
risk for hyponatremia
Possible additive risk for ↑ QTc

PD DI. Carbamazepine,
felbamate, phenytoin,
valproate
PD DI. Carbamazepine,
felbamate, phenytoin,
valproate

Agomelatine

Possible additive risk for hepatic injury

Bupropion, duloxetine, TCAs and
trazodone

Possible additive risk for hepatic injury

PD DI. Valproate
PD DI. Topiramate,
zonisamide rarely

SSRIs
TCAs and mirtazapine due to
antimuscarinic activity

Possible additive hemorrhagic risk
Both may be associated with heat stroke

If you use them, review other PK and PD DIs
Be aware
If you use them, review other PK and PD DIs
Mirtazapine and TCAs may have less risk for
nausea and may have anti-nausea effects in some
patients
Be aware if you combine them

Be particularly careful in geriatric females who
have more risk of developing hyponatremia.
Polydipsic patients with severe mental illness may
have hyponatremia risk with only one of these
drugs
Be vigilant (can be lethal)
Consider need for ECG
Torsades de pointes is very rare but additive risk
factors are family history of sudden death; personal
history of syncopes, arrhythmias or heart conditions; hypokalemia, hypomagnesemia, and coprescription of other medications that ↑ QTc. Cases
are more frequent in females aged > 65 years
In the US, consider legal risk. The FDA requires a
QTc warning for the use of high doses of
citalopram
Consider these warnings when co-prescribing
Be extremely careful when adding agomelatine to
these
antiepileptics
and
consider
other
antidepressants
Be very careful when adding these antidepressants
and antiepileptics; consider other alternatives and
monitor liver enzymes
These antidepressants should not be used in those
with prior history of liver injury secondary to
antiepileptics, or with current liver enzyme
elevations during antiepileptic treatment
Monitor closely if you decide to co-prescribe
In elderly and/or exposed to strenuous exercise or
high temperatures:
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Be vigilant (can be lethal). Encourage proper
hydration
Monitor closely if you decide to co-prescribe

PD DI. Carbamazepine,
SSRIs
Possible additive osteoporosis risk
phenobarbital, phenytoin,
primidone >2 oxcarbazepine,
topiramate, valproate
ADR: adverse drug reaction; PD DI: pharmacodynamic drug interaction; PK DI: pharmacokinetic drug interaction; SNRI: Serotonin and noradrenaline reuptake inhibitor; SSRI:
Selective serotonin reuptake inhibitor.
1
Reviewed PK DI studies were used to estimate correction factors, which are >1 in inducers and <1 in inhibitors. A correction factor of 2 indicates that you need to double the
dose for the same effect. A correction factor of 0.5 indicates that you need to halve the dose for the same effect. The further the correction factor is from 1, the more relevant the
DI may be. The therapeutic window or index also determines the clinical relevance of correction factors.
2
Drugs preceding ">" will produce a more powerful outcome than the drugs listed on the following line.
3
The bupropion correction factor is 10. It is so large that it appears better to avoid bupropion unless TDM is available.
4
The correction factor of 2 for TCAs is based on a decrease of 50% of plasma concentrations. As Table 3 shows, the decreases may range from 40% to 70%; this will provide a
correction factor ranging from 2.5 to 1.4. It is better to use TDM than correction factors to correct the dose in each patient more accurately.
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PHARMACOKINETICS OF ANTIEPILEPTICS FOR ENDOGENOUS
COMPOUNDS INFLUENCING SAFETY
OSTEOPOROSIS (after many years of treatment, making it difficult to establish frequencies)
Induction of Vitamin D metabolism
Carbamazepine, phenobarbital, phenytoin, primidone >1 oxcarbazepine, topiramate, valproate

THYROID DISTURBANCES (relatively uncommon)
Induction of thyroid hormone metabolism
Carbamazepine, phenytoin2

HYPERLIPIDEMIAS (there are no long-term prospective studies)
Induction of enzymes important for lipid metabolism
Carbamazepine, phenobarbital, phenytoin, primidone3

SEXUAL DISTURBANCES (clinical relevance is unclear)
Induction of sexual hormone metabolism4
Carbamazepine, phenobarbital, phenytoin

HYPERHOMOCYSTINEMIA (possible risk factor for atherosclerosis)
Disturbances of folic acid and vitamin B12 metabolism5

Carbamazepine, phenobarbital, phenytoin, primidone >1 oxcarbazepine, topiramate, valproate

Figure 1. Pharmacokinetics of antiepileptics for endogenous compounds influencing safety.
1
Drugs preceding ">" will produce this ADR more frequently than drugs following ">".
2
Oxcarbazepine may be associated with mild thyroid disturbances.
3
Valproate appears to decrease total and high-density lipoprotein (HDL) cholesterol by unknown
mechanisms.
4
Carbamazepine, phenobarbital and phenytoin may be associated with ↑increases in serum sex
hormone-binding globulin concentrations in both men and women. Over time, the ↑ increase in
serum sex hormone-binding globulin levels leads to ↓ testosterone and estradiol activity, which may
result in diminished potency in men and menstrual disorders in some women. Valproic acid
medication may have effects on serum androgen concentrations and it ↓ reduces serum follicle
stimulating hormone levels in men; clinical relevance is unknown. In fertile women with epilepsy,
there is more agreement that valproic acid may have clinical relevance and be associated with
polycystic changes in the ovaries, high serum testosterone concentrations (hyperandrogenism) and
menstrual disorders. These disorders are especially common among epileptic women who have
gained weight during valproic acid treatment. It is not established whether these changes occur in
non-epileptic women taking valproic acid for years.
5
Other abnormalities associated with folic acid deficits are gingival overgrowth associated with
phenytoin treatment and poor oral hygiene, and macrocytic anemia associated with phenytoin and
phenobarbital. It is believed that phenytoin may inhibit the folic acid transporter.
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PHARMACODYNAMICS FOR ANTIEPILEPTIC EFFICACY
ANTIEPILEPTIC ACTIVITY1
↓ Activity of voltage-dependent sodium channels

Carbamazepine, eslicarbazepine, felbamate, lacosamide, lamotrigine, oxcarbazepine, phenytoin, rufinamide, topiramate,
zonisamide

↓ Activity of voltage-dependent calcium channels
Ethosuximide, gabapentin, lamotrigine, pregabalin, topiramate, zonisamide

↑ GABA neurotransmission
Clobazam, felbamate, gabapentin, phenobarbital, pregabalin, primidone, stiripentol, tiagabine, topiramate, vigabatrin

Complex including ↑ GABA neurotransmission
Valproate

↓ Glutamatergic neurotransmission
Felbamate, topiramate

Complex: binds to synaptic vesicle protein 2A (↓ synaptic vesicle recycling and NT release)
Levetiracetam

Allosteric modulator which enhances the activity of the slow voltage-gated potassium channels
Retigabine

MOOD STABILIZER ACTIVITY2
At intracellular signaling system (inositol signaling)
Carbamazepine, valproate

Unknown mechanism
Lamotrigine

ANXIOLYTIC ACTIVITY
↑ GABA neurotransmission

Clobazam, pregabalin (off-label in the US)3

FOR PAIN4
↓ Activity of voltage-dependent sodium or calcium channels
Carbamazepine, gabapentin, oxcarbazepine, pregabalin

FOR MIGRAINE PROPHYLAXIS5
Unknown mechanism
Topiramate, valproate

↓ APPETITE AND WEGHT LOSS (off-label in the US)6
Inhibition of carbonic anhydrase
Topiramate, zonisamide

MENOPAUSAL VASOMOTOR SYMPTOMS (HOT FLASHES & NIGHT SWEATS)
Unknown mechanism
Gabapentin (off-label in the US)

Figure 2. Pharmacodynamics for antiepileptic efficacy.
This figure is an update from Figure 2 in a prior article [28].
1
Different articles describe different mechanisms of action for some drugs including levetiracetam,
valproate and zonisamide.
2
Antiepileptics approved in the US for bipolar disorder include: i) valproate for mania; ii)
carbamazepine for the treatment of acute manic and mixed episodes of bipolar disorder; and iii)
lamotrigine for prophylaxis, particularly of depressive phases. Treatment guidelines also consider:
i) valproate monotherapy or adjunctive therapy for bipolar depression or prophylaxis, ii)
carbamazepine monotherapy or adjunctive therapy for prophylaxis, and iii) lamotrigine
monotherapy or adjunctive therapy for bipolar depression. Gabapentin, lamotrigine and topiramate
mania RCTs were negative. Oxcarbazepine bipolar disorder RCTs appear promising. There are no
published RCTs for eslicarbazepine, levetiracetam or zonisamide.
3
Pregabalin is approved for generalized anxiety disorder in Europe but not in the US. Clobazam has
not been approved for anxiety in the US but has been widely used as an anxiolytic in other
countries. Other antiepileptics may have antianxiety properties.
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4

In the US approved drugs include: i) carbamazepine for trigeminal neuralgia, ii) gabapentin for
postherpetic neuralgia, and iii) pregabalin for postherpetic neuralgia and diabetic neuropathic pain.
Lacosamide is being studied in RCTs for diabetic neuropathic pain. Oxcarbazepine is usually
considered an alternative for trigeminal neuralgia when patients cannot tolerate carbamazepine.
Other antiepileptics, including levetiracetam, lamotrigine and phenytoin are considered by some
authors as acceptable treatments for neuropathic pain.
5
In the US, the only antiepileptics approved for migraine prophylaxis are topiramate and valproate.
6
Topiramate and zonisamide treatments are frequently associated with weight loss. In the US, the
combination of topiramate and phentermine (a sympathomimetic amine anorectic agent) has been
approved as an adjunctive treatment to a reduced-calorie diet and increased physical activity for
chronic weight management in obesity or overweight with complications.
NT; neurotransmitter; RTC: randomized clinical trial.
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PHARMACODYNAMICS FOR ANTIEPILEPTIC SAFETY
SEDATION (common)
Same mechanism that explains antiepileptic efficacy

FGAED and topiramate >1 other SGAEDs >1 felbamate, lacosamide, lamotrigine, tiagabine

COGNITIVE IMPAIRMENT(common)
Same mechanism that explains antiepileptic efficacy
Definitively in FGAEDs and probably in SGAEDs2

BALANCE DISTURBANCES AND/OR MOTOR OCULAR3 ADRs (common)
Same mechanisms that explain antiepileptic efficacy
Most AEDS

DEPRESSION4
↑ GABA neurotransmission

Phenobarbital, primidone, topiramate, vigabatrin (common) >1 zonisamide >1 felbamate, levetiracetam, tiagabine

VISUAL FIELD DEFECTS
Retinal accumulation of GABA
Vigabatrin (common) > rare in topiramate

WEIGHT GAIN (common in long-term treatment)
Unknown mechanism
Carbamazepine, gabapentin, pregabalin, retigabine, valproate

NAUSEA AND VOMITING (common)
↓ activity of voltage-dependent sodium channels
Carbamazepine, eslicarbazepine, felbamate, lacosamide, lamotrigine, oxcarbazepine, phenytoin, rufinamide, topiramate,
zonisamide

Unknown mechanism
Ethosuximide, levetiracetam, phenobarbital, tiagabine, valproate

HYPONATREMIA
SIADH and/or increase in ADH sensitivity

Oxcarbazepine (common) >1 carbamazepine >1 rare in other AEDs

COAGULATION IMPAIRMENT
Thrombocytopenia (mediated by toxic mechanisms)
Valproate (common and dose-related) >1 pregabalin

Interference with coagulation factors
Valproate (relatively uncommon)

PARADOXICAL SEIZURES (relatively uncommon)
Same mechanism that explains antiepileptic efficacy
Carbamazepine, tiagabine >1 other AEDs >1 valproate

ABUSE (relatively uncommon)
Same mechanism that explains antiepileptic efficacy
Clobazam, phenobarbital > lacosamide, pregabalin, retigabine > gabapentin

PSYCHOSIS (relatively uncommon)5
Unknown mechanism

Ethosuximide, levetiracetam, lamotrigine, retigabine, tiagabine, topiramate, vigabatrin, zonisamide

AGGRESSIVE BEHAVIOR (relatively uncommon)6
Unknown mechanism

Gabapentin, levetiracetam, lamotrigine, phenobarbital, topiramate, vigabatrin, zonisamide

HYPERAMMONEMIC ENCEPHALOPATHY (relatively uncommon)
Interference with urea cycle
Valproate

MOVEMENT DISORDERS (relatively uncommon)
Unknown mechanisms which vary according to type of movement disorder
Many AEDs

METABOLIC ACIDOSIS/UROLITHIASIS (relatively uncommon)
Inhibition of carbonic anhydrase
Topiramate, zonisamide
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↓ BLADDER CONTRACTILITY AND URINARY RETENTION (relatively uncommon)
↑Activity of bladder voltage-dependent potassium channels
Retigabine

LEUKOPENIA (relatively uncommon)
Unknown mechanism
Carbamazepine, ethosuximide, felbamate, phenobarbital, primidone, valproate

PR INTERVAL PROLONGATION (relatively uncommon)
↓ Activity of cardiac voltage-dependent sodium channels
Carbamazepine, lacosamide > lamotrigine, pregabalin

SUDDEN CARDIAC DEATH ASSOCIATED WITH ARRYTHMIAS
Antagonism of heart channels
QTc prolongation (relatively uncommon)
Retigabine

Torsades de pointes (very rare)6
Felbamate

Antagonism of heart sodium, potassium or calcium channel
Risk for patients with Brugada syndrome7
Avoid: oxcarbazepine. Preferably avoid: carbamazepine, lamotrigine, phenytoin

STEVENS–JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS
(very rare: 1-10/10,000-100,000)
Immunological mechanisms
Definitive: carbamazepine, ethosuximide, felbamate, lamotrigine, phenobarbital, phenytoin, primidone
Less well-established: oxcarbazepine, valproate, zonisamide

AGRANULOCYTOSIS AND/OR APLASTIC ANEMIA(very rare: 1-10/10,000-100,000)
Immunological mechanisms
Carbamazepine, ethosuximide, felbamate, phenobarbital, primidone, valproate

LIVER INJURY
Unknown mechanism
Liver enzyme elevations (common)
Most AEDs

Immune-allergic or toxic by metabolites
Life-threatening liver injury (rare)
Carbamazepine, felbamate, phenytoin, valproate

RISK FOR HEAT STROKE (rare)
Inhibition of carbonic anhydrase causes sweating inhibition
Topiramate, zonisamide

PANCREATITIS (rare)8
Unknown mechanism
Valproate

Figure 3. Pharmacodynamics for antiepileptic safety.
This figure is an update from Figure 3 in a prior article [28].
1
Drugs preceding ">" will produce this ADR more frequently than drugs following ">".
2
FGAEDs are associated with cognitive impairment in studies using neuropsychological testing.
There are few neuropsychological studies on SGAEDs. Various authors agree that phenobarbital
has the worst cognitive profile among FGAEDs, and topiramate among SGAEDs, but disagree on
the relative impairment associated with specific compounds and how topiramate compares with
FGAEDs.
3
They include diplopia and nistagmus.
4
Different reviews describe different frequencies for each AED-induced depression. A
comprehensive review described frequencies >10% for phenobarbital, primidone, topiramate and
vigabatrin; 7% for zonisamide in high doses; ≤ 4% for felbamate, levetiracetam and tiagabine; and
< 1% for the rest of the studied AEDs. On the other hand, carbamazepine, lamotrigine,
oxcarbazepine and valproate may have antidepressant properties in patients with epilepsy.
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It is difficult to assess when the psychosis is really an AED ADR rather than a manifestation of the
underlying or associated illnesses. Studies using lamotrigine and topiramate in bipolar disorder do
not describe increased psychotic symptoms.
6
It is difficult to assess when aggressive behavior is really an AED ADR rather than an underlying
or associated illness.
6
There is general agreement in the literature that most drugs that cause torsade de pointes can be
identified by assessing whether they block the human ether à gogo related gene (hERG) potassium
channel and prolong the QT interval on the electrocardiogram, but it is not well understood why
some drugs that block this channel do not cause torsades de pointes. Johannesen et al. [144] have
proposed that drugs that at the same concentration that block the inward calcium or sodium
channels they offset the pro-torsade effect of blocking the outward hERG potassium channels.
7
Brugada syndrome is identified by a specific ECG pattern (pseudo right bundle branch block and
persistent ST elevation in leads V1 to V3) and high incidence of ventricular fibrillation in the
absence of structural heart disease. Brugada syndrome is a channelopathy explained by genetic
abnormalities in the cardiac sodium, potassium or calcium channels.
8
The literature describes valproate-induced pancreatitis as very rare. A comprehensive review in
Germany indicated that milder cases are much more common than the literature suggests.
Pancreatitis may be particularly frequent in facilities for adults with intellectual disabilities.
ADR: adverse drug reaction; AED: antiepileptic drug; common: ADR ≥10% in RCT; FGAED:
first-generation antiepileptic drug; RTC: randomized clinical trial; SGAED: second-generation
antiepileptic drug; SIADH: syndrome of inappropriate antidiuretic hormone.

54

PHARMACODYNAMICS FOR ANTIDEPRESSANT EFFICACY
DEPRESSION1

Inhibitors of noradrenaline and serotonin transporter
Desvenlafaxine, duloxetine, levomilnacipran, milnacipran (not approved in the US), TCAs, and venlafaxine

Selective inhibitors of the serotonin transporter
All SSRIs

Selective inhibitors of the serotonin transporter and serotonin receptor antagonists2
Vilazodone and vortioxetine

Inhibitor of the noradrenaline and dopamine transporter2
Bupropion

Selective inhibitor of the noradrenaline transporter2
Reboxetine (not approved in the US)

5-HT2 antagonist (its major metabolite, m-CPP, is a 5-HT2C agonist)
Trazodone

α2 adrenergic receptor antagonist and/or 5-HT2A and 5-HT2C antagonist
Mirtazapine

Melatonergic analogue (MT1/MT2 agonist) and 5-HT2C antagonist
Agomelatine (not approved in the US)

OCD

Inhibitors of the serotonin transporter

Chlorimipramine, SSRIs (not all are approved in the US2)

ANXIETY

Same mechanism as antidepressant action3

Different compounds are approved for different disorders4 but specificity is doubtful

PAIN

Inhibition of the noradrenaline transporter5
TCAs are frequently used off-label
Duloxetine and milnacipran are approved in the US for fibromyalgia
Duloxetine is approved in the US for diabetic peripheral neuropathic and chronic musculoskeletal pain

MIGRAINE PROPHYLAXIS (off-label in the US)

Unknown mechanism
TCAs (amitriptyline is the most studied), less data exists on venlafaxine

WEIGHT LOSS

Inhibition of the dopamine transporter
Bupropion (off-label in the US)6

SMOKING CESSATION

Inhibition of the dopamine transporter
Bupropion

ATTENTION DEFICIT HYPERACTVITY DISORDER

Inhibition of the noradrenaline and dopamine transporter
Bupropion (off-label in the US)7

INSOMNIA
Antagonism of brain H1 receptors (daily sedation can be a problem)
Amitriptyline, mirtazapine, trazodone (off-label in the US)

Agonism of brain MT2 receptors
Agomelatine (not approved in the US)

CATAPLEXY
Suppression of REM sleep
TCAs, venlafaxine (off-label in the US)

SOME TYPES OF URINARY INCONTINENCE

Noradrenergic mechanisms are important
STRESS URINARY INCONTINENCE
Duloxetine (off-label in the US)8

NOCTURNAL ENURESIS IN CHILDREN
Imipramine
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MENOPAUSAL VASOMOTOR SYMPTOMS (HOT FLASHES & NIGHT SWEATS)
SNRIs, SSRIs (off-label in the US)

Unknown mechanism
Figure 4. Pharmacodynamics of efficacy for newer antidepressants. This figure is an update from
Figure 1 in a prior article [33].
1
Textbooks usually report that the majority of antidepressants act by inhibiting reuptake
transporters, but they also usually acknowledge that this is not a definitively proven theory, since
the chronology of reuptake inhibition does not match the chronology of antidepressant response.
2
Vilazadone is described as a dual-acting serotonergic antidepressant that combines selective 5-HT
reuptake inhibition with partial agonism of the 5-HT1A receptor. Vortioxetine is described as
combining 5-HT reuptake inhibition with 5-HT3A and 5-HT7 receptor antagonism, 5-HT1B receptor
partial agonism, 5-HT1A receptor agonism.
3
There are few attempts to describe the antidepressant pharmacological mechanism in anxiety
disorders; the literature usually assumes that the various antidepressants work in anxiety using the
same mechanism as in depression.
4
Fluoxetine, fluvoxamine, paroxetine and sertraline are approved in the US for OCD. SNRIs such
as duloxetine, desvenlafaxine and venlafaxine are used off-label.
4
Duloxetine, escitalopram, paroxetine, and venlafaxine are approved for generalized anxiety in the
US. Paroxetine, sertraline and venlafaxine are approved for social anxiety in the US. Paroxetine,
sertraline and venlafaxine are approved for panic disorders in the US. TCAs are considered an
effective off-label indication for panic disorder. A meta-analysis described the following newer
antidepressants as significantly superior to placebo for panic disorder patients with the following
increasing order of effectiveness: citalopram, sertraline, paroxetine, fluoxetine, and venlafaxine for
panic symptoms and paroxetine, fluoxetine, fluvoxamine, citalopram, venlafaxine, and mirtazapine
for overall anxiety symptoms. Aside from reboxetine and fluvoxamine, all drugs were associated
with significantly lower dropout rates as compared with placebo. Based on a few agomelatine RCTs
and uncontrolled studies, agomelatonine was considered a promising option when other
pharmacological treatments had failed in anxiety disorders. Vortioxetine has had inconsistent
results in generalized anxiety disorder RCTs.
5
It is believed that for pain treatment the inhibition of the norepinephrine transporter may be more
important than the inhibition of the serotonin transporter. There are antidepressant RCTs in pain
syndromes for fibromyalgia, painful diabetic neuropathy, postherpetic neuralgia, and neuropathic
pain (or painful neuropathy). Although venlafaxine is not approved in the US for pain, some RCTs
support its use. The benefits of duloxetine and milnacipran over placebo in fibromyalgia are small.
6
A meta-analysis indicated that weight loss with fluoxetine appears to be limited to the acute phase
of treatment. The combination bupropion-naltrexone is being studied in RCTs for weight loss.
7
According to a meta-analysis, bupropion is superior to placebo and effective in adults. There is
very limited data on other antidepressants.
8
Duloxetine can significantly improve the quality of life of patients with stress urinary incontinence,
but it is unclear whether or not benefits are sustainable.
5-HT: Serotonin receptor; α: Alpha adrenergic receptor; H: Histamine receptor; MT: Melatonin
receptors; OCD: Obsessive-compulsive disorder; RCT: Randomized clinical trial; TCA: tricyclic
antidepressant; SNRI: Serotonin and noradrenaline reuptake inhibitor; SSRI: Selective serotonin
reuptake inhibitor.
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PHARMACODYNAMICS FOR ANTIDEPRESSANT SAFETY1
BRAIN
WEIGHT GAIN1 (common in long-term)
Antagonism of brain H1
(antagonism of other receptors including M for TCAs and 5-HT2C for mirtazapine may contribute)
Amitriptyline, mirtazapine, paroxetine

↓ SEIZURE THRESHOLD (rarely relevant)

Unknown mechanism

Bupropion, TCAs>2placebo>2 some new antidepressants2,3

DECREASED DOPAMINERGIC ACTIVITY

Unknown mechanism
Akathisia (rare)
SSRIs

Other extrapyramidal symptoms (rare)
Probably all antidepressants4

Hyperprolactinemia (rare)
Probably all antidepressants5

PSYCHOTIC EXACERBATION (rare)6
Inhibition of the dopamine transporter
Bupropion

Unknown mechanism
TCAs

INSOMNIA

Different mechanisms7
Present in newer antidepressants except for agomelatine

PERIPHERAL (with/without brain component)
NAUSEA AND VOMITING (common)
Inhibition of the serotonin transporter8

Desvenlafaxine, duloxetine and venlafaxine >2SSRIs, vilazodone, vortioxetine >2 levomilnacipran and milnacipran

TACHYCARDIA and/or HYPERTENSION9 (relatively uncommon in RCTs)
Inhibition of the noradrenaline transporter

Desvenlafaxine, duloxetine (no hypertension), levomilnacipran, milnacipran, reboxetine, TCAs and venlafaxine

ORTHOSTATIC HYPOTENSION (relatively uncommon when appropriately titrated)
Antagonism of peripheral α1 receptors10
TCAs, trazodone

DIARRHEA (common)

Unknown mechanism

Sertraline,11 vilazodone and vortioxetine

SEXUAL ADRs (common)
Serotonergic mechanisms12
TCAs, SNRIs, SSRIs

Antagonism of peripheral α1 receptors
PRIAPISM (very rare)
Trazodone

HYPERLIPIDEMIA
Secondary to weight gain (see above) and direct effects on triglyceride levels
Mirtazapine

ANTICHOLINERGIC ADRs
Antagonism of peripheral muscarinic receptors
Tachycardia, constipation, dry mouth, urinary retention, blurred vision, ↓ sweating13
TCAs > mirtazapine, paroxetine and possibly reboxetine

Risk for heat stroke (rare but potentially lethal)
TCAs
URINARY SYMPTOMS (dysuria, urinary retention and sensation of incomplete bladder emptying)
Noradrenergic mechanisms are important
Desvenlafaxine, duloxetine, levomilnacipran, milnacipran, reboxetine and venlafaxine
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MYDRIASIS (risk for uncontrolled narrow-angle glaucoma)
Inhibition of the noradrenaline transporter
Desvenlafaxine, duloxetine, levomilnacipran, milnacipran, reboxetine, TCAs and venlafaxine

HYPERHIDROSIS (relatively uncommon)
Peripheral noradrenergic and central serotonergic mechanisms are important
Probably all antidepressants

OSTEOPOROSIS (after many years of treatment, making difficult to establish frequencies)
Serotonergic mechanisms at bone tissue
Probably SSRIs

DISCONTINUATION/WITHDRAWAL SYNDROME

Unknown mechanism

Newer antidepressants: acute headaches, dizziness and nausea14

Paroxetine and venlafaxine >2 other new >2 fluoxetine >2 agomelatine and reboxetine (absent)

Cholinergic rebound
TCAs: withdrawal symptoms after sudden discontinuation of high doses
TCAs

RISK FOR BLEEDING (rare but potentially lethal)
Serotonin depletion in platelets due to inhibition of serotonin transporter and other mechanisms15
SSRIs usually combined with other drugs with hemorrhagic risk or related to delivery or surgery

SEROTONIN SYNDROME (rare but potentially lethal)
Increased serotonin activity in brain and periphery
Usually requires combinations of several drugs increasing serotonin activity

ARRYTHMIAS
Antagonism of heart channels
QRS widening, QTc prolongation, and ventricular arrhythmias (relatively common in overdoses)
TCAs

Antagonism of heart repolarizing potassium channels
Torsades de pointes (very rare)16
Citalopram, fluoxetine, sertraline

Risk for patients with Brugada syndrome17
Antagonism of heart sodium, potassium or calcium channel
Preferably avoid: fluoxetine, fluvoxamine and paroxetine

NEUTROPENIA (rare)

Unknown mechanism
Mirtazapine

HYPONATREMIA (rare, more frequent in geriatric females)
SIADH and/or increase in ADH sensitivity18
Probably all antidepressants

LIVER INJURY

Unknown mechanism
Live enzyme elevations

Agomelatine (up to 5% in 50 mg/day) >2 probably rare in other antidepressants

Immune-allergic or toxic by metabolites
Life-threatening liver injury

Agomelatine >2 bupropion, duloxetine, TCAs, trazodone >2 other >2 citalopram, escitalopram, paroxetine and
fluvoxamine

Figure 5. Pharmacodynamics of safety antidepressants.
This figure is an update from Figure 2 in a prior article [33].
1
The more comprehensive review comparing antidepressant safety and meta-analysis of RCTs did
not include more recently marketed compounds. Agomelatine is a 5-HT2C antagonist. Insufficient
data is available on long-term treatment to rule it out as a cause of weight gain. Case reports
indicated some patients may gain significant weight with agomelatine long-term treatment.
2
Drugs preceding ">" will produce this ADR more frequently than drugs following ">".
3
A comprehensive literature review described bupropion as the only newer antidepressant
associated with increased seizure risk in RCTs.
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Extrapyramidal symptoms have been reported with different classes of antidepressants, are not
dose-related, and can develop with short-term or long-term use.
5
Symptomatic hyperprolactinemia has been reported with nearly all antidepressants. Incidence rates
are not clearly established and symptoms were very rare.
6
The literature is somewhat contradictory but, in selected cases, bupropion and TCAs appear to be
associated with the induction of psychotic symptoms, in addition to the precipitation or worsening
of an existing psychotic syndrome.
7
Proposed mechanisms: 1) SSRIs may cause insomnia by 5-HT2 stimulation; 2) SNRIs and
reboxetine may cause insomnia by blocking the noradrenaline transporter; and 3) mirtazapine may
have a reverse-dose response effect with sedation at lower doses and with insomnia at higher doses.
H1 antagonism is predominant at lower doses, while increased noradrenergic activity is
predominant at higher doses.
8
Nausea and vomiting are the most frequent causes of discontinuation of newer antidepressants
during the first 30 days of treatment. They are 10% more frequent in venlafaxine than in SSRIs.
There are no comparisons of vilazodone and vortioxetine with other newer antidepressants. The
estimate of the frequency of nausea is a rough estimate based on placebo-controlled RCTs.
Mirtazapine and TCAs may help with some types of nausea.
9
In a comprehensive review comparing newer antidepressant safety, venlafaxine was significantly
associated with hypertension when compared with other newer antidepressants. Desvenlafaxine and
milnacipran also appear to cause hypertension. Duloxetine has not been consistently associated
with hypertension; increases in blood pressure have been mild, but caution should be used in
patients with hypertension. Epidemiological studies have associated TCAs with hypertension.
10
Mirtazapine has very low affinity for α1 receptors and has rarely been associated with syncopes.
Venlafaxine has no affinity for α1 receptors but has been consistently associated with orthostatic
hypotension in geriatric patients.
11
Comprehensive reviews and meta-analyses agree that sertraline is associated with more diarrhea
risk than other newer antidepressants.
12
It has been proposed that sexual ADRS may be related to serotonergic stimulation of 5-HT2 and 5HT3 receptors, but their origin is complex, probably also involving the effect of 5-HT on nitric
oxide production as well as other systems. Bupropion and mirtazapine may be no different than
placebo. Agomelatine and reboxetine are probably associated with very low risk for sexual ADRs.
Vilazodone appears to have low risk for sexual ADRs but is associated with more sexual ADRs
than placebo.
13
Amitriptyline, clomipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine
have definitive antimuscarinic activity. Amoxapine, desimipramine, maprotiline, mirtazapine and
paroxetine have low antimuscarinic activity. Citalopram, escitalopram, fluoxetine, trazodone and
sertraline show antimuscarinic activity in some studies but not in all. Reboxetine frequently causes
dry mouth and constipation, and more rarely urinary retention. It has been proposed that the
noradrenergic mechanism may explain these antimuscarinic symptoms because 1) reboxetine’s
affinity for muscarinic receptors is too low to be relevant at therapeutic doses, and 2) no metabolites
with greater antimuscarinic activity have been identified.
14
SSRI discontinuation included somatic symptoms such as dizziness, lethargy, and sleep
disturbances, as well as psychological symptoms such as anxiety/agitation, irritability, and poor
concentration. The literature provides very limited information on possible mechanisms.
15
It has been proposed that an SSRI-induced increase in gastric acid secretion may explain the
gastrointestinal bleeding risk and that SSRI-related effects on platelet reactivity, endothelial
reactivity, and inflammatory markers may explain the protective effect against ischemic heart
disease.
16
A comprehensive literature review indicated that citalopram (8 cases), fluoxetine (6 cases) and
sertraline (1 case) can rarely be associated with torsades de pointes. There is general agreement in
the literature that most drugs that cause torsades de pointes can be identified by assessing whether
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they block the human ether à gogo related gene (hERG) potassium channel and prolong the QT
interval on the electrocardiogram, but it is not well understood why some drugs that block this
channel do not cause torsades de pointes. Johannesen et al. [144] have proposed that drugs at the
same concentration level that block the inward calcium or sodium channels also offset the protorsade effect of blocking the outward hERG potassium channels.
17
Brugada syndrome is described in footnote 7 of Figure 3.
18
All antidepressants are probably able to cause hyponatremia on rare occasions. It usually happens
in geriatric patients, particularly females. The literature usually describes these cases as SIADH but
it is not clear why antidepressants can cause SIADH.
5-HT: Serotonin receptor; ADR: Adverse drug reaction; common: ADR ≥ 10% in RCT; ECG:
Electrocardiogram; H: Histamine receptor; M: Muscarinic receptor; TCA: Tricyclic antidepressant;
RCT: Randomized clinical trial; SIADH: Syndrome of inappropriate antidiuretic hormone; SNRI:
Serotonin and noradrenaline reuptake inhibitor; SSRI: Selective serotonin reuptake inhibitor.

